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ABSTRACT 
Peritoneal dialysis (PD), an essential renal replacement therapy, remains limited by dialysis 
failure due to peritoneal membrane fibrosis. This is driven by peritoneal inflammation, caused by 
infections or sterile cellular stress during PD. Given the fundamental role of Toll-like receptors 
(TLRs) and complement in inflammation, we assessed the potential of peritoneal TLR2, TLR4, 
C5aR and C5L2 as therapeutic targets against PD-associated fibrosis. TLR2-, TLR4- and C5aR-
mediated pro-inflammatory and fibrotic responses to bacteria were consistent with the expression 
of these receptors in peritoneal macrophages (TLR2/4, C5aR) and mesothelial cells (TLR2, 
C5aR). In vivo, we found a major role for TLR2, to a lesser extent for TLR4, a supplementary 
role for C5aR and no apparent activity of C5L2 in infection-induced peritoneal fibrosis 
development. Similarly, TLR2, TLR4 and C5aR differentially contributed to bacteria-induced 
pro-fibrotic and inflammatory mediator production by peritoneal leukocytes from uremic PD 
patients ex vivo. TLR2, TLR4 and their co-receptor, CD14, were also involved in pro-fibrotic 
responses of uremic leukocytes to endogenous components present in non-infected patients’ PD 
effluent (PDE). Enhancing TLR-mediated inflammation increased fibrosis in vivo, pointing at 
TLRs as therapeutic targets. Soluble TLR2 (sTLR2), negative modulator of TLRs, was detected 
in PDE and inhibited PDE-induced TLR2- or TLR4-mediated pro-fibrotic responses. Notably, 
sTLR2 markedly reduced Gram-positive and Gram-negative bacteria-induced fibrosis in vivo, 
inhibiting pro-inflammatory and fibrotic genes without affecting infection clearance. These 
findings reveal peritoneal TLR2 and TLR4’s influence on PD-associated infection-induced and 
sterile fibrosis, and describe a therapeutic strategy to reduce fibrosis by targeting TLRs and 
CD14 with sTLR2. 
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INTRODUCTION 
Peritoneal dialysis (PD) depends on the structural and functional integrity of the 
peritoneal membrane. A major factor limiting PD remains peritoneal membrane failure, which is 
directly related to progressive thickening of the sub-mesothelial compact zone, termed fibrosis, 
resulting in altered solute transport and dialysis failure. This process is driven by peritoneal 
inflammation, caused by recurrent infections or by ongoing cellular stress and tissue injury 
induced by the dialysis process (sterile inflammation).1 The mechanisms linking inflammation 
with the genesis and regulation of fibrosis remain to be fully elucidated2, 3 and effective therapies 
to prevent this PD-associated pathology are still to be developed. 
Toll-like receptors (TLRs) are critical to triggering a rapid inflammatory response to 
clear infections4. They are expressed in various cell types, including peritoneal mesothelial 
cells,5 and recognise microorganisms and their components as well as host endogenous 
molecules released following cellular stress (e.g., High Mobility Group Box-1 (HMGB-1); heat 
shock proteins), or generated as a consequence of matrix degradation during tissue injury (e.g., 
hyaluronan, fibronectin).6, 7 TLR triggering leads to the release of pro-inflammatory and fibrotic 
mediators, e.g. IL-6, TGF-β, TNF-α, IL-8.3, 8 
The complement system also plays a fundamental role in inflammation. Complement 
activation leads to generation of C5a, a potent pro-inflammatory peptide with activities including 
leukocyte chemoattraction and pro-inflammatory cytokine and chemokine induction. C5a 
induces responses through the C5a receptor (C5aR). A second C5a receptor, C5L2, can inhibit 
C5aR.9-11 We and others have demonstrated crosstalk between TLRs and C5aR, by which cell 
exposure to a combination of TLR ligands and C5a results in synergistically enhanced pro-
inflammatory mediator production.12-15 
Given the serious inflammatory conditions resulting from TLR and/or C5aR over-
activation, TLRs and C5a receptors are attractive therapeutic targets for the treatment and/or 
prevention of inflammation-associated pathologies.16-19 In this study, we assessed the potential of 
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peritoneal TLRs, C5aR and C5L2 as therapeutic targets against peritoneal fibrosis development 
during PD by investigating their influence on pro-inflammatory and fibrotic responses in vitro, 
ex vivo and in vivo. The study reveals the major influence that TLR2 and TLR4, and to a lesser 
extent C5aR, exert on infection-associated and sterile peritoneal inflammation and fibrosis 
development. It demonstrates the therapeutic potential of a TLR targeting strategy to prevent 
PD-associated fibrosis that is based on the modulatory capacity of the soluble form of TLR2. 
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RESULTS 
Differential expression and response of TLR2, TLR4 and C5aR in human resident 
peritoneal leukocytes and mesothelial cells  
We first examined the expression and response of TLR2, TLR4 – the TLRs recognising the 
widest range of microbial components involved in PD-associated infections – and C5aR in the 
main peritoneal cell types involved in the initial response to danger: resident macrophages, 
lymphocytes and mesothelial cells (Figure 1A). PD effluent (PDE)-isolated resident 
macrophages showed high levels of TLR2 and C5aR expression and moderate levels of TLR4, 
whereas mesothelial cells (from greater omentum) and PDE lymphocytes showed very modest 
levels of TLR2 and C5aR, and undetectable (mesothelial cells) or barely detectable 
(lymphocytes) levels of TLR4. The TLR co-receptor CD14, which enhances TLR-mediated 
responses,20 was strongly expressed in peritoneal macrophages, but barely detectable in 
lymphocytes and mesothelial cells. The C5aR modulatory receptor, C5L2, was expressed in all 
the cell types tested at moderate (macrophages and mesothelial cells) or low (lymphocytes) 
levels. 
Consistent with the expression of the corresponding receptors, TLR2, TLR4 and C5aR 
agonists triggered pro-inflammatory responses in PDE leukocytes, as judged by the release of the 
polymorphonuclear (PMN) chemoattractant CXCL8/IL-8 induced by Pam3-Cys-Ser-(Lys)4 
(Pam3Cys, a synthetic bacterial lipopeptide), the Gram-positive bacterium Staphylococcus 
epidermidis (both TLR2 agonists21, 22), the Gram-negative bacterial cell-wall component 
lipopolysaccharide (LPS) and Escherichia coli (both TLR4 agonists23, 24) as well as by the C5aR 
ligand, C5a (Figure 1B). The C5a stimulation profile observed here was similar to that shown by 
peripheral blood mononuclear cells (PBMC),15 with reduced stimulation as the C5a 
concentration increases and the negative regulator C5L2 becomes engaged. Leukocyte responses 
were mainly driven by macrophages (Figure 1B), as expected given their high receptor 
expression levels compared with lymphocytes (Figure 1A). Mesothelial cells responded to 
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Pam3Cys, S. epidermidis, E. coli and C5a, but not to LPS (Figure 1B). Their lack of LPS-induced 
response confirmed our previous findings,5 since human mesothelial cells did not express TLR4 
(Figure 1A). However, they responded to E. coli, probably at least partly through the TLR2-
mediated recognition of bacterial lipopeptides25 and the expression of TLR5,5 which recognises 
flagellin, the protein component of the flagellum found in Gram-negative bacteria.26 
Synergism between TLRs and C5aR in the pro- and anti-inflammatory and fibrotic 
responses of peritoneal leukocytes, but not of mesothelial cells 
We tested whether crosstalk between TLRs and C5aR operates in peritoneal cells, as is the case 
in PBMC, resulting in the synergistic enhancement of responses (Supplemental Figure 1 and ref. 
15). Co-stimulation of PDE-isolated leukocytes with Pam3Cys and C5a resulted in a marked 
enhancement of IL-8 release compared with the estimated additive effect of each ligand (Figure 
2A). A much lower, but significant, synergistic effect was observed upon LPS+C5a stimulation 
(Figure 2A). By contrast, peritoneal mesothelial cells co-stimulated with varying concentrations 
of Pam3Cys+C5a, LPS+C5a or E. coli+C5a did not show a synergistic response (Figure 2B). Of 
note and similar to PBMC,15 the TLR-C5aR crosstalk in peritoneal leukocytes appears to be 
negatively regulated by C5L2, as blocking C5L2 with a specific mAb substantially increased the 
synergistic response to Pam3Cys+C5a (Figure 2C). Together, these findings indicated the 
existence of a C5L2-regulated pro-inflammatory TLR-C5aR crosstalk in peritoneal leukocytes, 
but not in mesothelial cells, by which concerted stimulation via TLR2 – or to a lesser extent via 
TLR4 – and C5aR imparts hypersensitivity to leukocytes to the cognate ligands.  
 The potential impact of peritoneal leukocyte TLR2-C5aR crosstalk on fibrosis 
development was evaluated by testing for synergism in the release of pro- and anti-inflammatory 
and fibrotic mediators (Figure 2D). Pam3Cys+C5a induced a marked synergistic enhancement in 
the release of the pro-fibrotic cytokines TGF-β and IL-1327-29. By contrast, the release of other 
pro-fibrotic and pro-inflammatory cytokines i.e., IL-6 and TNF-α, and the anti-inflammatory and 
anti-fibrotic cytokine IL-10 showed either a very modest enhancement (IL-6, TNF-α) or only an 
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additive effect (IL-10) (Figure 2D). Matrix metalloproteinases (MMPs), which are involved in 
both augmenting and attenuating fibrosis,30 were only slightly affected by the TLR2-C5aR 
crosstalk (Figure 2D), with a very modest increase upon Pam3Cys stimulation at low C5a 
concentrations (MMP-1, MMP-9) and a stronger synergistic enhancement at higher C5a 
concentration (MMP-1, MMP-3, MMP-9). By contrast, the effect of TLR2-C5aR crosstalk on a 
negative regulator of MMPs, tissue inhibitor of metalloproteinases-1 (TIMP-1), was marked and 
at low C5a concentrations (Figure 2D). These data indicated synergism between TLR2 and C5aR 
in the release of pro- and anti-inflammatory and fibrotic mediators, with a differential effect 
depending on the mediator. 
Contribution of TLR2, TLR4 and C5aR, but not C5L2 to peritoneal fibrosis development 
in bacteria-induced mouse peritonitis models  
We next evaluated the relevance of peritoneal TLR- and C5a receptor-mediated responses to PD-
associated bacteria-induced peritoneal fibrosis development in vivo. We used our established3 
murine model of recurrent bacteria-induced peritoneal inflammation leading to fibrosis. In this 
model, the key features of repeated clinical bacterial peritonitis episodes with the eventual 
development of peritoneal fibrosis typically observed in PD patients are mimicked by the weekly 
peritoneal injection (4 injections) of a previously defined dose of whole (heat-killed or live) S. 
epidermidis (TLR2 agonist; a main causative pathogen of PD-associated peritonitis) or E. coli 
(TLR4 agonist) (Supplemental Figure 2 and Concise Methods), both reported to trigger 
complement activation and C5a generation.31, 32 Four weeks after the fourth 
infection/inflammatory episode, peritoneal fibrosis is measured in sections of parietal membrane. 
Repeated intraperitoneal injection of heat-killed S. epidermidis in wild-type (WT) mice resulted 
in substantial peritoneal fibrosis (Figure 3A). Notably, fibrosis was not observed following S. 
epidermidis injection in TLR2-deficient (TLR2-/-) mice (Figure 3A). By contrast, TLR4-/- mice 
injected with E. coli showed a partial (~45%) reduction in fibrosis when compared with WT 
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mice (Figure 3B), consistent with the possibility that, in addition to TLR4, other receptors (e.g. 
TLR2, TLR5) may be involved in E. coli-induced pro-fibrotic responses.  
The role of C5aR and C5aR-TLR2 crosstalk in fibrosis development in mice was also 
investigated. The repeated injection of heat-killed S. epidermidis in C5aR-/- mice resulted in 
moderate (~40%) fibrosis reduction when compared with WT mice (Figure 3C). This contrasted 
with the dramatic effect of TLR2 deficiency, which completely prevented fibrosis development 
(Figure 3A). These findings indicated a prominent role of TLR2 in S. epidermidis-induced 
peritoneal fibrosis development. Furthermore, the absence of fibrosis in the S. epidermidis-
injected TLR2-/- mice suggested that the locally generated C5a may induce fibrosis mainly 
indirectly, by enhancing TLR2-mediated responses through the C5aR-TLR2 crosstalk. This 
putative enhancement may explain the ~40% reduction in fibrosis observed in the S. 
epidermidis-injected C5aR-/- mice (Figure 3C). We therefore tested whether C5L2, which 
controls peritoneal C5aR-TLR2 crosstalk in vitro (Figure 2C), also modulates fibrosis 
development in vivo. Fibrosis was comparable between S. epidermidis-injected WT and C5L2-/- 
mice (Figure 3D), suggesting that the TLR2-C5aR crosstalk signal intermediates involved in pro-
fibrotic responses are not controlled by C5L2 or, most likely, that C5L2 controls equally both the 
pro- and anti-fibrotic signalling demonstrated to be positively affected by TLR2-C5aR crosstalk 
(Figure 2D). Collectively, these findings indicated a major role for TLR2, to a lesser extent for 
TLR4 and only a supplementary role for C5aR in bacteria-induced peritoneal fibrosis, but no 
apparent net influence of C5L2.  
Differential contribution of TLR2, TLR4 and C5aR to bacteria-induced pro-fibrotic and 
inflammatory mediator release by peritoneal leukocytes from uremic PD patients 
The clinical relevance of the findings described above was evaluated by testing whether the 
uremic milieu, present in PD patients, has an effect on the observed role of TLR2, TLR4 and 
C5aR in bacteria-induced peritoneal fibrosis development. To this end, the involvement of these 
receptors was evaluated in uremic peritoneal leukocytes isolated from non-infected PDE of 
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patients whose uremic status was confirmed (urea and creatinine levels in PDE and blood). 
Consistent with the findings obtained by using the mouse peritonitis model (Figure 3), blocking 
TLR2, TLR4 and C5aR with specific mAbs significantly reduced S. epidermidis- and E. coli-
induced pro-fibrotic (IL-13, TGFβ, IL-6) and inflammatory (IL-6, IL-8) cytokine release by 
uremic leukocytes. The extent of the blocking effect depended on the individual, the bacterium 
and the cytokine tested (Figure 4), with TLR2 blockade consistently showing a significant effect 
on pro-fibrotic cytokine release. 
 We also analysed fibrosis-related gene expression in uremic leukocytes following 
bacterial stimulation and TLR2 blockade. An inhibitory effect of TLR2 blockade on the capacity 
of S. epidermidis to induce mRNA coding for a number of fibrosis markers was observed (Table 
1). Twenty three of the 84 genes tested were significantly induced (P≤ 0.05; fold change ≥ 2) by 
S. epidermidis (full list of genes in Supplemental Table 1). Notably among the transcripts 
markedly reduced by blocking TLR2, was that coding for Snail, a transcription factor master 
regulator of epithelial-mesenchymal transition, a process that plays a critical role in fibrosis 
development33. TLR2 blockade also inhibited a number of Mmps transcripts. Tgf-β transcription 
was not induced by S. epidermidis at the time point tested (Supplemental Table 1). However, the 
release of this pro-fibrotic cytokine was induced by S. epidermidis after 72h, indicating slower 
transcription kinetics for this cytokine, and TLR2 blockade reduced this effect markedly (Figure 
4). Together, these findings obtained using patients’ uremic peritoneal leukocytes tested in a 
uremic milieu, provided proof of concept for the clinical relevance of the differential 
involvement of peritoneal TLR2, TLR4 and C5aR in pro-fibrotic and inflammatory responses 
induced by bacteria. 
Involvement of TLR2, TLR4, CD14 and C5aR in PD-induced sterile peritoneal 
inflammation 
To further assess the clinical relevance of peritoneal TLRs and C5aR to PD-associated fibrosis, 
their involvement in PD-induced sterile inflammation was investigated. Uremic peritoneal 
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leukocytes isolated from non-infected PDE, were cultured overnight with non-infected cell-free 
PDE in the absence or presence of TLR2-, TLR4- or C5aR-specific blocking mAbs. The PDE 
used for stimulation also served to maintain uremic conditions throughout the experiment 
(Figure 5, A and B). PDE from non-infected PD patients induced pro-fibrotic (IL-13, TGFβ, IL-
fhyk6) and inflammatory (IL-6, IL-8, TNF-α) responses in the uremic leukocytes (Figure 5, A 
and B). These responses were reduced by anti-TLR2, -TLR4 or both mAbs to a varying extent 
depending on the individual and the PDE tested. TLR2 blockade showed however an overall 
more consistent effect on pro-fibrotic cytokine release. Additional blocking experiments 
demonstrated that TLR-mediated peritoneal leukocyte responses to PDE were heavily dependent 
on the TLR co-receptor CD14, irrespective of the TLR (TLR2 or TLR4) involved (Figure 5, A 
and B). By contrast, blocking C5aR did not, or very modestly, affect leukocyte responses (Figure 
5, A and B). Notably, production of IL-6 and TNF-α - pro-inflammatory and fibrotic mediators 
reported to be important determinants of peritoneal inflammation and peritoneal solute transport 
in the uninfected state1- was mostly not affected by C5aR blocking (Figure 5, A and B). 
Similarly, the levels of the pro-fibrotic cytokines TGF-β and IL-13 were not, or very modestly 
affected, depending on the patient, by C5aR blockade (Figure 5A). These findings indicated that 
while PD may induce complement production and its activation in the uninfected state, as was 
reported,34-37 the direct or indirect (via TLR crosstalk) involvement of complement in pro-
inflammatory and fibrotic processes in non-infected patients is modest at best, and depends on 
the patient. In addition, the peritoneal C5a levels in most patients may be extremely low due to 
dilution in the peritoneum during dialysis, resulting in minimal C5aR activation. 
 Analysis of fibrosis-related gene expression in uremic leukocytes following non-infected 
cell-free PDE stimulation and TLR2 blockade further confirmed the involvement of TLR2 in 
fibrosis processes (Table 2), Only seven of the 84 genes tested were found affected by PDE 
stimulation at this time point (full list of genes in Supplemental Table 2), with TLR2 blockade 
markedly inhibiting Ccl2 (MCP-1), Egf and Mmp13 (Table 2). Tgf-β transcription was not 
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induced by PDE at this time point (Supplemental Table 2). However, TGF-β release was induced 
by PDE after 72h, indicating slower transcription kinetics for this cytokine, and blocking TLR2 
reduced its release markedly (Figure 5A). Collectively, these findings indicated that peritoneal 
TLR2, TLR4 and their main co-receptor, CD14, drive pro-fibrotic and inflammatory responses 
not only to microbial components, but also to host endogenous components that may be present 
in the uremic peritoneum as a consequence of cellular stress or tissue injury induced during PD.1 
Consistent with this possibility, we found HMGB-1 (TLR2/TLR4 ligand38, 39) in PDE of non-
infected PD patients, confirming a previous finding,40 and its expression varied between patients 
(Figure 5C). 
Impact of TLR2-mediated inflammation intensity on bacterial infection-induced peritoneal 
fibrosis development  
To evaluate the importance of peritoneal TLR-mediated inflammation intensity in infection-
induced fibrosis development, we used a TLR2-derived peptide – peptide 9 – which we 
demonstrated amplifies TLR2-mediated inflammation by targeting the TLR co-receptor CD14, 
enhancing its activity.20 By using the in vivo peritoneal fibrosis model described previously, we 
found that live S. epidermidis infection in the presence of peptide 9 substantially increased 
peritoneal fibrosis, as compared with mice infected with bacteria in the absence of peptide 
(Figure 6A). The marked increase in fibrosis in the S. epidermidis+peptide 9 mice correlated 
with higher peritoneal inflammation (higher numbers of PMN and monocytes recruited to the 
peritoneum, Figure 5A inset). Of note, the TLR2-derived control peptide 17 did not affect 
inflammatory cell recruitment (Figure 6A inset). Consistent with the higher number of recruited 
phagocytes, peptide 9 accelerated bacterial clearance (Figure 6A inset). Notably, despite the 
accelerated infection resolution in the presence of the pro-inflammatory peptide, fibrosis was 
more severe – probably as a consequence of the enhanced inflammation.  
 To evaluate the importance of intensity of inflammation over number of infections in 
peritoneal fibrosis development, mice were injected only twice (one/week) with S. epidermidis ± 
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the TLR2-boosting peptide. Fibrosis was not detected following two infection episodes, even in 
the presence of the pro-inflammatory peptide (Figure 6B). Together, these findings indicated 
that, in addition to the number of infection episodes, but irrespective of their duration, the 
intensity of the resulting inflammation seriously impacts on fibrosis development. This pointed 
at controlling the intensity of the CD14/TLR-mediated inflammation as a therapeutic strategy 
against peritoneal fibrosis. 
Peritoneal expression and inflammation regulatory capacity of the TLR inhibitor soluble 
TLR2  
To test whether the intensity of the TLR-mediated peritoneal inflammation is naturally 
controlled, we tested for the peritoneal presence of the natural inhibitor of TLRs, soluble TLR2 
(sTLR2), which we previously detected in plasma41 and demonstrated to reduce TLR-mediated 
inflammation by acting as a decoy receptor and also by interfering with CD14’s co-receptor 
activity.42 We detected sTLR2 in PDE from non-infected patients, and its level varied between 
patients (Figure 7A). The source of sTLR2 was mainly the TLR2-expressing macrophages 
(Figures 7B and 1A), as PDE-isolated macrophages released sTLR2 upon activation, whereas 
sTLR2 was barely detectable or undetectable in the culture supernatants of peritoneal 
lymphocytes and mesothelial cells (Figure 7B). sTLR2 concentrations were significantly 
increased in PDE from patients with ongoing bacterial peritonitis (Figure 7C), and the levels 
declined over time, as the infection resolved (Figure 7D).  
We next evaluated the capacity of endogenous peritoneal sTLR2 to control inflammatory 
responses. Depleting sTLR2 from cell-free non-infected PDE significantly increased PDE’s 
stimulatory capacity (Figure 7E), suggesting that the pro-inflammatory capacity of endogenous 
peritoneal TLR ligands is inhibited by peritoneal sTLR2. Of note, inhibition by sTLR2 was 
observed in PDE activating cells via TLR2 and TLR4 or mostly via TLR4 (shown here PDE#2 
stimulating patient E’ leukocytes, Figure 5A and B), suggesting that not only the TLR ligand but 
also the co-receptor CD14 was targeted for modulation. Importantly, supplementing cell-free 
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PDE from non-infected or infected patients with purified sTLR2 reduced PDE’s stimulatory 
capacity (Figure 7F), suggesting that, in addition to its natural activity, sTLR2 may be of 
therapeutic value against infection-induced and sterile peritoneal inflammation and fibrosis 
development in PD.  
Reduction of bacterial-induced peritoneal fibrosis by therapeutic administration of soluble 
TLR2 
We next tested the therapeutic potential of sTLR2 against PD-induced fibrosis in vivo. 
Administration of sTLR2 together with the repeated injection of live S. epidermidis prevented 
fibrosis development (Figure 8A). This was accompanied by a marked reduction in the 
peritoneal levels of the pro-inflammatory mediators KC (murine functional counterpart of human 
IL-8) and MCP-1, prototypical PMN, and monocyte chemoattractants, respectively (Figure 8B). 
This in turn resulted in a reduced number of PMN and monocytes recruited to the peritoneum at 
the peak time of their influx (Figure 8B).  
Analysis of fibrosis-related gene transcripts conducted one week after the last injection 
(day 28, before fibrosis becomes detectable), showed a marked inhibitory effect of sTLR2 on the 
capacity of S. epidermidis to induce mRNA coding for a number of pro-inflammatory mediators 
and fibrosis markers (Table 3 and Figure 8C; full list of genes in Supplemental Table 3). Twenty 
one of the 85 genes tested were significantly induced (P≤ 0.05; fold change ≥ 2) by S. 
epidermidis at this time point, and sTLR2 reduced this effect in 18 of them. Among the 
transcripts affected by sTLR2 was Fasl. FasL is central to apoptosis, a cell death mechanism that 
impairs bacterial clearance during PD and induces peritoneal macrophage death, increases 
peritoneal inflammation and the production of PMN chemoattractants.43, 44 The negative effect 
on Fasl was prolonged, as it was also observed after 4 weeks following the last infection (day 49, 
Table 2). sTLR2 administration also inhibited the S. epidermidis-induced transcription of signal 
transducer and activator of transcription-1 (STAT-1) (Table 1), a critical signal intermediate for 
fibrosis development in this model.3 Together with STAT-1, IFN-γ was shown to mediate 
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peritoneal fibrosis,3 however, sTLR2 did not significantly affect the strong S. epidermidis-
induced transcription of IFN-γ (Table 3). sTLR2 may nevertheless affect IFN-γ’s pro-fibrotic 
effect indirectly, through its inhibitory effect on STAT-1 – a main signal intermediate 
downstream of the IFN-γ receptor. sTLR2 also inhibited the S. epidermidis-induced transcription 
of IL-6 (Table 3), a major driver of peritoneal fibrosis.3 Notably, sTLR2 counteracted the 
negative effect of S. epidermidis on Mmp-1, Mmp-3 and Mmp-9 observed relatively late (day 49, 
Table 4), and the relatively early (day 28) S. epidermidis’ positive effect on Mmp-13 and the 
MMP inhibitor Timp-1 (Table 3). sTLR2’s effect on Timp-1 was maintained until day 49 (Table 
4). sTLR2 showed an apparent strong positive effect on Tnf-α transcription at day 28 (Table 3), 
however, this effect was not noticeable at day 49, indicating probably a delayed transcription 
kinetics rather than an increase in transcript level in the presence of sTLR2. Similarly, an effect 
on transcription kinetics may explain sTLR2’s apparent positive effect on Ccl3/Mip-1α (Table 
3). Transcription of the pro-fibrotic cytokine TGF-β was not induced by S. epidermidis either at 
day 28 or 49 (Supplemental Table 3), whereas its receptor was induced by S. epidermidis and 
inhibited by sTLR2 at day 28 (Table 3). However, analysis of TGF-β levels in peritoneal lavages 
of mice at 3, 6 and 12 h post-infection, showed induction of TGF-β by S. epidermidis and a 
marked reduction following administration of sTLR2+S. epidermidis (Figure 8D). 
Of note, the reduced inflammation and phagocyte recruitment in the presence of sTLR2 
did not affect the capacity of the mice to clear the infection, as no difference in bacterial load 
(peritoneum and blood) between sTLR2-treated and -non-treated mice was observed (Figure 8E). 
This is likely due to the fact that reduced PMN recruitment was significant at the peak of their 
influx (~12h), and by this time the mice had cleared the infection almost completely. In addition, 
other immune mechanisms (e.g. complement activation) likely contribute to bacterial clearance. 
 The fibrosis-preventing capacity of sTLR2 extended to fibrosis induced by Gram-
negative bacteria. Administration of sTLR2 together with E. coli resulted in reduced peritoneal 
fibrosis (Figure 8F), although moderate (~35%) when compared with that exerted on S. 
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epidermidis-induced fibrosis (Figure. 8A). This reflects the fact that sTLR2 does not operate as a 
TLR decoy receptor for most Gram-negative bacterial components, but can still reduce Gram-
negative bacteria-induced TLR-mediated fibrotic signalling by inhibiting CD14, a co-receptor 
for most TLRs42. Thus, the therapeutic administration of sTLR2 can inhibit peritoneal fibrosis 
development induced by repeated peritoneal bacterial infections by acting on a number of pro-
inflammatory and fibrotic mediators, but critically, without affecting infection resolution. 
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DISCUSSION 
Peritoneal fibrosis, and the concomitant functional alterations in the peritoneal membrane, is a 
major cause of PD cessation. It is detected, to a variable extent, in approximately 50% and 80% 
of patients within one and two years on PD, respectively.45-47 Peritoneal inflammation is a major 
driver of fibrosis, and treatment options to reduce or prevent it have been suggested.1 They 
include: strategies to improve residual renal function to limit the production and activity of 
inflammatory cytokines; the use of biocompatible PD solutions to reduce peritoneal membrane 
injury and cellular stress; the use of catheters resistant to bacterial biofilm formation; the use of 
twin-bags, Y-set systems and antibiotic administration prior to PD catheter insertion to prevent 
peritoneal infection, and improvement in fluid status to prevent endotoxemia. In addition, 
strategies to inhibit the pro-fibrotic activity of TGF-β have been evaluated.48 However, a limited 
number of intervention studies have not yet been able to define effective strategies to 
consistently lower the inflammatory burden in these patients.1 Critically, studies to identify the 
main peritoneal receptors involved in triggering the initial pro-inflammatory and fibrotic 
responses, and to develop therapeutic strategies to reduce their activation have not been 
conducted. Here, we identified peritoneal TLR2 and TLR4 as critical pro-inflammatory and 
fibrotic receptors and revealed their potential as therapeutic targets against PD-associated 
fibrosis development. We described a therapeutic strategy that targets TLRs by using a decoy 
soluble receptor, sTLR2, which also inhibits the activity of the common TLR co-receptor CD14, 
thus reducing pro-inflammatory and fibrotic responses to different pathogens and endogenous 
TLR ligands. 
The therapeutic potential of targeting TLRs was highlighted by the pivotal role that TLR2 
and TLR4 activation showed in microbial- and sterile inflammation-induced pro-fibrotic 
responses in vivo and ex vivo in patients’ uremic leukocytes, and the conclusive demonstration 
that the intensity of the TLR-mediated pro-inflammatory responses dictates the severity of 
peritoneal fibrosis. Thus, an efficient therapy against peritoneal fibrosis should not only treat 
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recurrent infections, but also reduce the severity of inflammatory episodes. In this regard, the 
observation that in our in vivo model of bacteria-induced fibrosis the transcript levels of many 
inflammatory and fibrotic mediators remained elevated long after the resolution of the infectious 
episode (a finding in agreement with previous reports in clinical PD49, 50) highlights the need for 
a therapy capable of maintaining low levels of these mediators, like the one proposed here. 
The potential of sTLR2 as an efficient therapy was further demonstrated by its ability to 
inhibit peritoneal inflammation and fibrosis development in mice without affecting their capacity 
to clear the infection. This presents a clear advantage over strategies to block TLR activation 
completely, for example by using antibodies, as these would be predicted to have a detrimental 
effect on infection clearance. Preclinical studies have however evaluated combining anti-
TLR2/TLR4 antibodies with broad spectrum antibiotics to achieve strong anti-inflammatory 
effects whilst controlling infection.51, 52 Thus, a comparative evaluation of the sTLR2 strategy 
and these alternative therapies in PD models of infection/fibrosis will be required. It also remains 
to be assessed the efficacy of sTLR2 either as a preventive or therapeutic treatment, since in the 
present in vivo study it was administered together with the infecting bacteria. Due to its ability to 
target both the TLR ligand and the common TLR co-receptor, CD14, sTLR2 presents a dual 
therapeutic benefit, as demonstrated here by its capacity to inhibit proinflammatory and fibrotic 
responses in models of Gram-positive as well as Gram-negative bacterial peritoneal infections 
and in patients’ sterile PDE activating cells via TLR2 or TLR4. The sTLR2-based anti-fibrotic 
strategy described here could thus prove to be a valuable adjunct to standard antibiotic therapies 
during PD infections or to more biocompatible PD solutions. sTLR2’s capacity to modulate 
CD14 activity would also be potentially useful against fungal and viral infections in which TLRs 
other than TLR2 and TLR4 are involved. It may also be potentially useful in fibrosis-associated 
conditions of organs such as the kidney, lung and liver and in other PD-associated inflammatory 
conditions, for example to help reduce the elevated risk of cardiovascular diseases.53 
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CONCISE METHODS 
Cells and PD Effluent 
Samples from healthy individuals (omentum, blood) and PD patients (spent PD dialysate) were 
obtained in accordance with the institutional review board of Cardiff University and the local 
National Health Service Research Ethics Committee. Written informed consent was obtained 
from all donors. Sampling was carried out within the UK Clinical Research Network under study 
portfolios ID #11838 (PERITPD) and ID #11839 (LEUKPD) and adhered to the Declaration of 
Helsinki. Spent PD dialysates were obtained from continuous ambulatory PD patients following 
an overnight dwell). Resident peritoneal leukocytes were obtained by centrifugation (2 times, 
425 x g x 15 min, 4 °C) of non-infected dialysates and were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 10% foetal calf serum (FCS, HyClone; < 0.06 U/mL endotoxin; 
heat-inactivated, 56 °C, 30 min). The cell-free (centrifuged) dialysate supernatants were 
aliquoted and kept frozen (-85 °C) until further use. To confirm the uremic status of the patients, 
the levels of urea and creatinine in the PDE and blood were tested (Cardiff and Vale University 
Hospital, clinical Pathology laboratory). Uremia was defined as urea > 7.8 mM and creatinine > 
110 µM (UK-wide criteria defined by the NHS).  
Peritoneal lymphocytes and macrophages were isolated from freshly-prepared PDE-leukocytes 
following adhesion (2h, 37 °C) in the absence of serum. The purity of the macrophage (adherent 
fraction, ≥ 90%) and lymphocyte (non-adherent fraction, ≥ 95%) populations was determined by 
flow cytometry, based on their forward and side scatter properties and CD14 expression levels. 
Cell viability was assed using the eFluor viability dye (eBioscience) and was always ≥85%. 
Peritoneal mesothelial cells were prepared by tryptic digest of omental biopsies obtained 
following elective surgery of non-PD patients, as previously described,5 and cultured in M199 
medium (Invitrogen) supplemented with insulin (0.5 μg/ml), transferrin (0.5 μg/ml), and 10% 
FCS.  
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Human PBMC were obtained through Ficoll density-gradient centrifugation and cultured in 
RPMI 1640 medium supplemented with 10% FCS.  
Functional Assays 
For activation experiments (Figures 1, 2 and 4), triplicate aliquots of peritoneal leukocytes, 
lymphocytes, macrophages and PBMC (1.5 x 104 cells/well, in 96-well plates) or mesothelial 
cells (4 x 104 cells/well, in 48 well-plates), were cultured in the presence of the indicated 
concentrations of ultra-pure LPS (E. coli O111:B4 strain; Invivogen), the synthetic bacterial 
lipopeptide Pam3-Cys-Ser-(Lys)4 HCl (EMC microcollections), heat-killed E. coli (O111:B4 
strain; Invivogen) or heat-killed (20 min, 100 °C) S. epidermidis (ATCC 12228), in the absence 
or presence of the indicated concentrations of purified human C5a (Comptech). For the 
experiments shown in Figure 4, the medium was supplemented with the patients' own PDE (1:2 
dilution) in order to maintain the uremic milieu throughout the experiment. Cell culture 
supernatants were collected for cytokine assays following 16h stimulation. For TGF-β 
determinations, cells were washed (RPMI 1640) after 48h stimulation and cultured for a further 
24h in the absence of FCS before culture supernatants were collected. Supernatants were tested 
for IL-8, TGF-β, IL-13 and TIMP-1 by ELISA (R&D Systems) and IL-6, TNF-α, IL-10, MMP-
1, MMP-3 and MMP-9 by using the multiplex ELISA platform Meso Scale Discovery. RNA was 
extracted and gene array analyses were performed as described below. 
For testing cell responses to sterile cell-free PDE supernatants (Figure 5), peritoneal leukocytes 
(1.5 x 104 cells/well) were stimulated with PDE (1:2 dilution) from patients with no ongoing 
clinical peritoneal infection and no history of infection in the 6 months prior to PDE collection. 
The sterility of the cell-free PDE used was confirmed by negative bacterial growth (on 
microbiological agar plates) and bacterial DNA detection by qPCR. Briefly, total DNA was 
extracted from cell-free PDE of non-infected patients by a chelex-based method as previously 
described.54 One PDE sample was spiked with heat-killed S. epidermidis prior to extraction to 
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serve as a positive control. Pan-bacterial DNA was then amplified by qPCR using the Femto
TM
 
Bacterial DNA Quantification kit (Zymo research), and the amount of DNA in PDE was 
determined using the kit’s internal standard curve as a reference. A Ct of 30 cycles, 
corresponding to 10 fg of bacterial DNA per 1ml of PDE, was set as cut off for PDE sterility 
(Supplemental Figure 3). 
sTLR2 depletion from PDE before cell stimulations was performed as previously described41 by 
sequential immunoprecipitations (4 rounds) with the purified polyclonal anti-TLR2 Ab TLR2p 
(generated in our laboratories41 by immunization with an N terminus 20-mer TLR2 peptide, 
SKEESSNGASLSGDRNGIGK) or isotype control (mock depletion; purified rabbit Igs, Sigma). 
The extent of the sTLR2 depletion was up to 85%, depending on the experiment, as judged by 
Western blotting followed by densitometric analysis of the gels. In some experiments (Figure 7) 
sTLR2 levels in PDE were determined by ELISA (R&D Systems). For the experiment shown in 
Figure 7F, PDE-induced cell stimulation was conducted in the presence of human recombinant 
soluble TLR2 (500 ng/ml, R&D). 
For blocking experiments, cells were preincubated (30 min at 37 °C) with 5 μg/ml of functional 
grade anti-TLR2 (clone T2.5, eBioscience), anti-TLR4 (clone3C3, Hycult), anti-CD14 (clone 
MY4, Beckman Coulter) or anti-C5aR (clone S5/1, Hycult) blocking mAbs or the corresponding 
isotype-matched control.  
Flow Cytometry 
TLR2, TLR4, CD14 and C5aR cell surface expression was determined by flow cytometry as 
previously described55 using anti-TLR2 (clone T2.5), anti-TLR4 (clone 15C1), anti-CD14 (clone  
MY4) and anti-C5aR (clone S5/1) mAbs and isotype-matched controls. To determine C5L2 
expression levels, staining with a PE-conjugated anti-C5L2 specific mAb (clone 1D9, 
Biolegend) was performed at room temperature, to allow for Ab internalisation and detection of 
intracellular C5L2. Peritoneal lymphocytes and macrophages were identified in the peritoneal 
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leukocyte preparations from PDE by their CD14 staining and forward and side scatter profiles 
(Supplemental Figure 4). Cell viability (eFluor viability dye) was always ≥85%. 
In Vivo experiments 
All procedures were carried out under a Home Office project license. Inbred 8 to 10-wk-old 
wild-type (C57/BL6J, C57BL/10J and BALB/cJ), TLR2-/- (B6.129-Tlr2tm1Kir/J), TLR4-/- 
(C57BL/10ScNJ) and C5aR-/- (C.129S4(B6)-C5ar1tm1Cge/J) mice were obtained from Jackson 
laboratories, and C5L2-/- mice (on a BALB/c background) were bred and maintained in J. Köhl’s 
laboratory, Germany. Mice were intraperitoneally inoculated with PBS (500 μl), SES (a S. 
epidermidis cell-free supernatant prepared as previously described56), heat-killed or live S. 
epidermidis (5 x 108 CFU/mouse) or heat-killed E. coli (2 x 107 CFU/mouse), in the absence or 
presence of previously defined optimal doses of the TLR2-derived peptide 9 
(TNSLIKKFTFRNVKITDESLFQVMKLLN, 20 μg/mouse, > 95% pure, Lifetein)20 or human 
recombinant soluble TLR242 (250 ng/mouse). Injections were repeated weekly, for 4 or 2 weeks 
as indicated, and mice were then left untreated for a week (Day 28) or 4 weeks (Day 49) before 
parietal peritoneal membrane was collected for fibrosis assessment. Through the use of this 
model (4 injections, one/week), fibrosis became detectable at day 49 following repeated injection 
with SES and whole (heat-killed or live) S. epidermidis or E. coli as well as by injection of PBS, 
albeit to a much lesser extent (Supplemental Figure 2). The latter most likely resulted from 
sterile inflammation induced by tissue injury/cellular stress. SES, S. epidermidis and E. coli are 
known to induce cell responses mainly via TLR2 (SES,5 S. epidermidis21) and TLR4 (E. coli23, 
24).  
For determination of leukocyte numbers, cytokine levels and bacterial load, mice were sacrificed 
at the indicated time points after the first injection, their peritoneal cavity was lavaged with 2 ml 
of ice-cold PBS, and peripheral blood was obtained by cardiac puncture. Leukocyte numbers in 
the lavages were determined by Coulter counting (Coulter Z2, Beckman-Coulter) and differential 
double staining (anti-Ly6-PE, BD; anti-7/4-A647, Serotec) followed by flow cytometric analysis. 
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Cytokine levels were determined by ELISA, and bacterial CFU in peritoneal lavages and blood 
samples, by culturing on Mueller-Hinton agar plates (Oxoid) overnight at 37 °C. 
Peritoneal Membrane Histology 
Peritoneal membrane biopsies were fixed (24h, 4 °C) with a neutral buffered 10% formalin 
solution (Sigma) saline embedded in paraffin, and sections (5 μm thickness) were stained with 
hematoxylin and eosin. Slides were analysed with a Leica DFC49 microscope (×40 objective) 
and camera, and the thickness of the submesothelial cell compact zone (SMC) was measured as 
previously described.3 Briefly, three different fields of view were examined for each mouse, 6 
measurements were made per field and the average of the 10 highest measurements was taken as 
mean of SMC thickness for each animal.  
Western Blotting  
The Western Blot technique was as previously described.57 Cell-free PDE samples were diluted 
1/20 in Laemmli reducing sample buffer and subjected to 10% SDS-PAGE prior to Western blot 
analysis using the anti-TLR2 polyclonal Ab TLR2p described above (1/2000) or an anti-HMGB1 
polyclonal Ab (Ab18256, Abcam, 1/1000). Densitometric analysis was performed using the 
ImageJ software. 
Fibrosis-focused Gene Arrays 
Total RNA was isolated from peritoneal leukocytes or mice peritoneal membranes using the 
RNeasy mini kit (Qiagen). Reverse transcription-polymerase chain reaction (RT-PCR) was 
performed on 200 ng of RNA using the RT2 first strand kit (Qiagen, including a genomic DNA 
elimination step). Fibrosis gene array RT-qPCR was performed on the resulting complementary 
DNA (cDNA) using the human or mouse fibrosis RT2 Profiler PCR Array (85 genes; Qiagen) 
and the ABI ViiA7TM thermocycler. The results were analysed using Qiagen software. Changes 
in gene expression compared to control were considered statistically significant when P<0.05, 
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and biologically relevant when the fold change was ≤ 0.5 or ≥ 2, as recommended by the 
manufacturer. The complete data set is shown in Supplemental Table 1. 
Statistical Analysis 
Statistical analysis of the data was performed by using an unpaired Student’s t test. P values of 
less than 0.05 were considered significant. 
 
ACKNOWLEDGMENTS 
We thank M. López-Cabrera (Centro de Biología Molecular-Severo Ochoa-CSIC, Madrid, 
Spain), C. Fielding (Cardiff University, UK), and J. E. Rey Nores (Cardiff Metropolitan 
University, UK) for critical comments and reading of the manuscript.  
This work was supported by grants from The National Institute of Social Care and Health 
Research (NISCHR), Wales (to M.O.L. and M.E.); NISCHR and Kidney Research UK (KRUK) 
Fellowships (to A.-C.R.); KRUK project grant (to M. E.) and SFB/TR22 of the Deutsche 
Forschung Germany (J.K.). 
 
DISCLOSURES 
None 
 
 
 
 
  
24 
 
REFERENCES  
1. Cho, Y, Hawley, CM, Johnson, DW: Clinical causes of inflammation in peritoneal dialysis patients. 
International journal of nephrology, 2014: 909373, 2014. 
2. Lambie, M, Chess, J, Donovan, KL, Kim, YL, Do, JY, Lee, HB, Noh, H, Williams, PF, Williams, AJ, Davison, 
S, Dorval, M, Summers, A, Williams, JD, Bankart, J, Davies, SJ, Topley, N, Global Fluid Study, I: 
Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. 
Journal of the American Society of Nephrology : JASN, 24: 2071-2080, 2013. 
3. Fielding, CA, Jones, GW, McLoughlin, RM, McLeod, L, Hammond, VJ, Uceda, J, Williams, AS, Lambie, 
M, Foster, TL, Liao, CT, Rice, CM, Greenhill, CJ, Colmont, CS, Hams, E, Coles, B, Kift-Morgan, A, 
Newton, Z, Craig, KJ, Williams, JD, Williams, GT, Davies, SJ, Humphreys, IR, O'Donnell, VB, Taylor, 
PR, Jenkins, BJ, Topley, N, Jones, SA: Interleukin-6 signaling drives fibrosis in unresolved 
inflammation. Immunity, 40: 40-50, 2014. 
4. Kawai, T, Akira, S: The role of pattern-recognition receptors in innate immunity: update on Toll-like 
receptors. Nat Immunol, 11: 373-384, 2010. 
5. Colmont, CS, Raby, AC, Dioszeghy, V, Lebouder, E, Foster, TL, Jones, SA, Labeta, MO, Fielding, CA, 
Topley, N: Human peritoneal mesothelial cells respond to bacterial ligands through a specific 
subset of Toll-like receptors. Nephrology, dialysis, transplantation : official publication of the 
European Dialysis and Transplant Association - European Renal Association, 26: 4079-4090, 
2011. 
6. Chen, GY, Nunez, G: Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol, 10: 826-
837, 2010. 
7. Anders, HJ, Schaefer, L: Beyond tissue injury-damage-associated molecular patterns, toll-like 
receptors, and inflammasomes also drive regeneration and fibrosis. Journal of the American 
Society of Nephrology : JASN, 25: 1387-1400, 2014. 
8. Kawasaki, T, Kawai, T: Toll-like receptor signaling pathways. Frontiers in immunology, 5: 461, 2014. 
9. Rittirsch, D, Flierl, MA, Nadeau, BA, Day, DE, Huber-Lang, M, Mackay, CR, Zetoune, FS, Gerard, NP, 
Cianflone, K, Kohl, J, Gerard, C, Sarma, JV, Ward, PA: Functional roles for C5a receptors in sepsis. 
Nat Med, 14: 551-557, 2008. 
10. Chen, NJ, Mirtsos, C, Suh, D, Lu, YC, Lin, WJ, McKerlie, C, Lee, T, Baribault, H, Tian, H, Yeh, WC: C5L2 
is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature, 446: 203-207, 
2007. 
11. Bamberg, CE, Mackay, CR, Lee, H, Zahra, D, Jackson, J, Lim, YS, Whitfeld, PL, Craig, S, Corsini, E, Lu, B, 
Gerard, C, Gerard, NP: The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal 
transduction. J Biol Chem, 285: 7633-7644. 
12. Riedemann, NC, Guo, RF, Hollmann, TJ, Gao, H, Neff, TA, Reuben, JS, Speyer, CL, Sarma, JV, Wetsel, 
RA, Zetoune, FS, Ward, PA: Regulatory role of C5a in LPS-induced IL-6 production by neutrophils 
during sepsis. Faseb J, 18: 370-372, 2004. 
13. Zhang, X, Kimura, Y, Fang, C, Zhou, L, Sfyroera, G, Lambris, JD, Wetsel, RA, Miwa, T, Song, WC: 
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood, 
110: 228-236, 2007. 
14. Wang, M, Krauss, JL, Domon, H, Hosur, KB, Liang, S, Magotti, P, Triantafilou, M, Triantafilou, K, 
Lambris, JD, Hajishengallis, G: Microbial hijacking of complement-toll-like receptor crosstalk. Sci 
Signal, 3: ra11. 
15. Raby, AC, Holst, B, Davies, J, Colmont, C, Laumonnier, Y, Coles, B, Shah, S, Hall, J, Topley, N, Kohl, J, 
Morgan, BP, Labeta, MO: TLR activation enhances C5a-induced pro-inflammatory responses by 
negatively modulating the second C5a receptor, C5L2. Eur J Immunol, 41: 2741-2752, 2011. 
16. Kanzler, H, Barrat, FJ, Hessel, EM, Coffman, RL: Therapeutic targeting of innate immunity with Toll-
like receptor agonists and antagonists. Nat Med, 13: 552-559, 2007. 
17. Dunne, A, Marshall, NA, Mills, KH: TLR based therapeutics. Curr Opin Pharmacol, 11: 404-411, 2011. 
18. Mollnes, TE, Christiansen, D, Brekke, OL, Espevik, T: Hypothesis: combined inhibition of complement 
and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol, 
632: 253-263, 2008. 
25 
 
19. Riedemann, NC, Guo, RF, Ward, PA: Novel strategies for the treatment of sepsis. Nat Med, 9: 517-
524, 2003. 
20. Raby, AC, Holst, B, Le Bouder, E, Diaz, C, Ferran, E, Conraux, L, Guillemot, JC, Coles, B, Kift-Morgan, A, 
Colmont, CS, Szakmany, T, Ferrara, P, Hall, JE, Topley, N, Labeta, MO: Targeting the TLR co-
receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science 
translational medicine, 5: 185ra164, 2013. 
21. Strunk, T, Power Coombs, MR, Currie, AJ, Richmond, P, Golenbock, DT, Stoler-Barak, L, Gallington, 
LC, Otto, M, Burgner, D, Levy, O: TLR2 mediates recognition of live Staphylococcus epidermidis 
and clearance of bacteremia. PloS one, 5: e10111, 2010. 
22. Zahringer, U, Lindner, B, Inamura, S, Heine, H, Alexander, C: TLR2 - promiscuous or specific? A critical 
re-evaluation of a receptor expressing apparent broad specificity. Immunobiology, 213: 205-224, 
2008. 
23. Hoshino, K, Takeuchi, O, Kawai, T, Sanjo, H, Ogawa, T, Takeda, Y, Takeda, K, Akira, S: Cutting edge: 
Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for 
TLR4 as the Lps gene product. J Immunol, 162: 3749-3752, 1999. 
24. Roger, T, Froidevaux, C, Le Roy, D, Reymond, MK, Chanson, AL, Mauri, D, Burns, K, Riederer, BM, 
Akira, S, Calandra, T: Protection from lethal gram-negative bacterial sepsis by targeting Toll-like 
receptor 4. Proc Natl Acad Sci U S A, 106: 2348-2352, 2009. 
25. Elson, G, Dunn-Siegrist, I, Daubeuf, B, Pugin, J: Contribution of Toll-like receptors to the innate 
immune response to Gram-negative and Gram-positive bacteria. Blood, 109: 1574-1583, 2007. 
26. Hayashi, F, Smith, KD, Ozinsky, A, Hawn, TR, Yi, EC, Goodlett, DR, Eng, JK, Akira, S, Underhill, DM, 
Aderem, A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. 
Nature, 410: 1099-1103, 2001. 
27. Kaviratne, M, Hesse, M, Leusink, M, Cheever, AW, Davies, SJ, McKerrow, JH, Wakefield, LM, Letterio, 
JJ, Wynn, TA: IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta 
independent. J Immunol, 173: 4020-4029, 2004. 
28. Leask, A, Abraham, DJ: TGF-beta signaling and the fibrotic response. FASEB J, 18: 816-827, 2004. 
29. Pohlers, D, Brenmoehl, J, Loffler, I, Muller, CK, Leipner, C, Schultze-Mosgau, S, Stallmach, A, Kinne, 
RW, Wolf, G: TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochimica 
et biophysica acta, 1792: 746-756, 2009. 
30. Giannandrea, M, Parks, WC: Diverse functions of matrix metalloproteinases during fibrosis. Disease 
models & mechanisms, 7: 193-203, 2014. 
31. Verbrugh, HA, Van Dijk, WC, Peters, R, Van Der Tol, ME, Verhoef, J: The role of Staphylococcus 
aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement 
activation and opsonization. Immunology, 37: 615-621, 1979. 
32. Harboe, M, Garred, P, Lindstad, JK, Pharo, A, Muller, F, Stahl, GL, Lambris, JD, Mollnes, TE: The role 
of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol, 189: 
2606-2613, 2012. 
33. Lamouille, S, Xu, J, Derynck, R: Molecular mechanisms of epithelial-mesenchymal transition. Nature 
reviews Molecular cell biology, 15: 178-196, 2014. 
34. Tang, S, Leung, JC, Chan, LY, Tsang, AW, Chen, CX, Zhou, W, Lai, KN, Sacks, SH: Regulation of 
complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis 
fluid. Clinical and experimental immunology, 136: 85-94, 2004. 
35. Young, GA, Kendall, S, Brownjohn, AM: Complement activation during CAPD. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and Transplant Association - 
European Renal Association, 8: 1372-1375, 1993. 
36. Reddingius, RE, Schroder, CH, Daha, MR, Willems, HL, Koster, AM, Monnens, LA: Complement in 
serum and dialysate in children on continuous ambulatory peritoneal dialysis. Peritoneal dialysis 
international : journal of the International Society for Peritoneal Dialysis, 15: 49-53, 1995. 
37. Yewdall, VM, Boscoe, MJ, Bennett-Jones, DN, Cameron, JS: Clinical applications of crossed 
immunoelectrophoresis to the study of complement activation. Journal of clinical & laboratory 
immunology, 24: 51-56, 1987. 
26 
 
38. Kim, S, Kim, SY, Pribis, JP, Lotze, M, Mollen, KP, Shapiro, R, Loughran, P, Scott, MJ, Billiar, TR: 
Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages 
requires CD14. Mol Med, 19: 88-98, 2013. 
39. Huebener, P, Schwabe, RF: Regulation of wound healing and organ fibrosis by toll-like receptors. 
Biochimica et biophysica acta, 1832: 1005-1017, 2013. 
40. Cao, S, Li, S, Li, H, Xiong, L, Zhou, Y, Fan, J, Yu, X, Mao, H: The potential role of HMGB1 release in 
peritoneal dialysis-related peritonitis. PloS one, 8: e54647, 2013. 
41. LeBouder, E, Rey-Nores, JE, Rushmere, NK, Grigorov, M, Lawn, SD, Affolter, M, Griffin, GE, Ferrara, P, 
Schiffrin, EJ, Morgan, BP, Labeta, MO: Soluble forms of Toll-like receptor (TLR)2 capable of 
modulating TLR2 signaling are present in human plasma and breast milk. J Immunol, 171: 6680-
6689, 2003. 
42. Raby, AC, Le Bouder, E, Colmont, C, Davies, J, Richards, P, Coles, B, George, CH, Jones, SA, Brennan, 
P, Topley, N, Labeta, MO: Soluble TLR2 reduces inflammation without compromising bacterial 
clearance by disrupting TLR2 triggering. J Immunol, 183: 506-517, 2009. 
43. Catalan, MP, Esteban, J, Subira, D, Egido, J, Ortiz, A, Grupo de Estudios Peritoneales de Madrid, FI: 
Inhibition of caspases improves bacterial clearance in experimental peritonitis. Peritoneal 
dialysis international : journal of the International Society for Peritoneal Dialysis, 23: 123-126, 
2003. 
44. Hohlbaum, AM, Gregory, MS, Ju, ST, Marshak-Rothstein, A: Fas ligand engagement of resident 
peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic 
factors. J Immunol, 167: 6217-6224, 2001. 
45. Garosi, G, Di Paolo, N: Morphological aspects of peritoneal sclerosis. Journal of nephrology, 14 Suppl 
4: S30-38, 2001. 
46. Garosi, G, Di Paolo, N: Pathophysiology and morphological clinical correlation in experimental and 
peritoneal dialysis-induced peritoneal sclerosis. Advances in peritoneal dialysis Conference on 
Peritoneal Dialysis, 16: 204-207, 2000. 
47. Schneble, F, Bonzel, KE, Waldherr, R, Bachmann, S, Roth, H, Scharer, K: Peritoneal morphology in 
children treated by continuous ambulatory peritoneal dialysis. Pediatric nephrology, 6: 542-546, 
1992. 
48. Tomino, Y: Mechanisms and interventions in peritoneal fibrosis. Clinical and experimental 
nephrology, 16: 109-114, 2012. 
49. Lai, KN, Lai, KB, Lam, CW, Chan, TM, Li, FK, Leung, JC: Changes of cytokine profiles during peritonitis 
in patients on continuous ambulatory peritoneal dialysis. American journal of kidney diseases : 
the official journal of the National Kidney Foundation, 35: 644-652, 2000. 
50. Yung, S, Chan, TM: Pathophysiological changes to the peritoneal membrane during PD-related 
peritonitis: the role of mesothelial cells. Mediators of inflammation, 2012: 484167, 2012. 
51. Spiller, S, Elson, G, Ferstl, R, Dreher, S, Mueller, T, Freudenberg, M, Daubeuf, B, Wagner, H, 
Kirschning, CJ: TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-
negative sepsis in mice. J Exp Med, 205: 1747-1754, 2008. 
52. Lima, CX, Souza, DG, Amaral, FA, Fagundes, CT, Rodrigues, IP, Alves-Filho, JC, Kosco-Vilbois, M, Ferlin, 
W, Shang, L, Elson, G, Teixeira, MM: Therapeutic Effects of Treatment with Anti-TLR2 and Anti-
TLR4 Monoclonal Antibodies in Polymicrobial Sepsis. PloS one, 10: e0132336, 2015. 
53. Fassett, RG, Driver, R, Healy, H, Coombes, JS: Cardiovascular disease in peritoneal dialysis patients. 
Panminerva medica, 51: 151-161, 2009. 
54. Walsh, PS, Metzger, DA, Higushi, R: Chelex 100 as a medium for simple extraction of DNA for PCR-
based typing from forensic material. BioTechniques 10(4): 506-13 (April 1991). BioTechniques, 
54: 134-139, 2013. 
55. Rey Nores, JE, Bensussan, A, Vita, N, Stelter, F, Arias, MA, Jones, M, Lefort, S, Borysiewicz, LK, 
Ferrara, P, Labeta, MO: Soluble CD14 acts as a negative regulator of human T cell activation and 
function. Eur J Immunol, 29: 265-276, 1999. 
56. Hurst, SM, Wilkinson, TS, McLoughlin, RM, Jones, S, Horiuchi, S, Yamamoto, N, Rose-John, S, Fuller, 
GM, Topley, N, Jones, SA: Il-6 and its soluble receptor orchestrate a temporal switch in the 
pattern of leukocyte recruitment seen during acute inflammation. Immunity, 14: 705-714, 2001. 
27 
 
57. Durieux, JJ, Vita, N, Popescu, O, Guette, F, Calzada-Wack, J, Munker, R, Schmidt, RE, Lupker, J, 
Ferrara, P, Ziegler-Heitbrock, HW, et al.: The two soluble forms of the lipopolysaccharide 
receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol, 24: 
2006-2012, 1994. 
 
 Table 1. Effect of blocking TLR2 in uremic peritoneal leukocytes on S. epidermidis-induced fibrosis-related gene expression.* 
  
S. epidermidis 
S. epidermidis + anti-
TLR2 
Anti- TLR2 
modulatory 
effect 
(%)*** 
Gene 
symbol 
Description 
Fold 
Change ** P-value ** 
Fold 
Change**  P-value **  
Ccl11 Chemokine (C-C motif) ligand 11 0.5 0.018 0.7 0.137 -34.7 
Ccl2 Chemokine (C-C motif) ligand 2 12.0 0.001 14.5 0.001 22.5 
 Ccl3 Chemokine (C-C motif) ligand 3, MIP1a 16.5 0.001 3.2 0.065 -86.0 
Ccr2 Chemokine (C-C motif) receptor 2 0.3 0.010 0.4 0.015 -11.2 
Ctgf Connective tissue growth factor 0.4 0.048 0.4 0.040 - 
Edn1 Endothelin 1 14.9 0.001 11.0 0.006 -28.2 
Grem1 Gremlin 1 0.2 0.001 0.4 0.001 -13.6 
Ifng Interferon gamma 55.2 0.001 63.5 0.001 15.4 
Il10 Interleukin 10 240.8 0.001 188.9 0.001 -21.7 
Il13 Interleukin 13 10.1 0.026 9.5 0.047 -5.6 
Il1a Interleukin 1, alpha 19.7 0.001 18.9 0.001 -4.0 
Il1b Interleukin 1, beta 31.8 0.011 30.1 0.004 -5.5 
Itga1 Integrin, alpha 1 9.5 0.001 9.4 0.001 -1.9 
ItgaV Integrin, alpha V 2.6 0.004 3.3 0.002 40.7 
Itgb3 Integrin, beta 3 5.7 0.001 6.6 0.002 17.6 
Itgb5 Integrin, beta 5 0.3 0.001 0.3 0.004 - 
Itgb8 Integrin, beta 8 12.6 0.004 13.7 0.011 9.4 
Mmp1 Matrix metallopeptidase 1 67.1 0.001 61.1 0.001 -9.0 
Mmp14 Matrix metallopeptidase 14 3.6 0.013 2.6 0.203 -38.9 
Mmp3 Matrix metallopeptidase 3 5.5 0.001 3.6 0.001 -41.7 
Mmp8 Matrix metallopeptidase 8 3.5 0.001 4.7 0.002 44.8 
Plg Plasminogen 2.8 0.031 1.0 0.903 -100.0 
Serpina1 Serpin peptidase inhibitor, clade A 9.7 0.001 8.8 0.001 -10.3 
Snai1 Snail homolog 1 7.2 0.049 5.3 0.063 -31.2 
Stat1 Signal transducer and activator of transcription 1, 91kDa 2.5 0.010 2.6 0.012 10.9 
Tgif1 TGFB-induced factor homeobox 1 2.3 0.032 2.3 0.041 - 
Timp3 TIMP metallopeptidase inhibitor 3 0.3 0.001 0.3 0.001 - 
Timp4 TIMP metallopeptidase inhibitor 4 0.4 0.021 0.4 0.022 - 
Tnf Tumor necrosis factor 4.9 0.002 4.7 0.001 -6.5 
Vegfa Vascular endothelial growth factor A 6.8 0.001 6.8 0.001 - 
*Only statistically significant (P<0.05) S. epidermidis-induced ≤ 0.5 (bold gold) or ≥ 2 (bold red) fold changes were considered.  
**Compared to Control group. 
***Compared to the effect of S. epidermidis treatment. Genes affected ≥20% are shown in blue (inhibition) or green (upregulation). 
 
 
 
Table 2. Effect of blocking TLR2 in uremic peritoneal leukocytes on non-infected PD effluent-induced fibrosis-related gene 
expression.* 
  
Non-infected PDE 
Non-infected  PDE + anti-
TLR2 
Anti- TLR2 
modulatory 
effect 
(%)*** 
Gene 
symbol 
Description 
Fold 
Change ** P-value ** 
Fold 
Change**  P-value **  
Ccl2 Chemokine (C-C motif) ligand 2 2.2 0.017 1.1 0.883 -91.0 
Egf Epidermal growth factor 6.5 0.001 1.1 0.835 -98.9 
Il13 Interleukin 13 3.5 0.001 3.9 0.011 16.8 
Il13ra2 Interleukin 13 receptor, alpha 2 7.3 0.002 6.7 0.004 -8.3 
Il4 Interleukin 4 4.2 0.001 3.8 0.014 -11.2 
Mmp13 Matrix metallopeptidase 13 4.1 0.001 1.1 0.835 -98.0 
Smda3 SMAD family member 3 0.4 0.019 0.2 0.005 31.0 
*Only statistically significant (P<0.05) PDE#1-induced ≤ 0.5 (bold gold) or ≥ 2 (bold red) fold changes were considered.  
**Compared to Control group. 
***Compared to the effect of S. epidermidis treatment. Genes affected ≥20% are shown in blue (inhibition) or green (upregulation). 
 
2 
 
Table 3. Changes in fibrosis-related peritoneal gene expression at day 28 in mice infected with S. epidermidis or S. 
epidermidis + sTLR2.* 
  S. epidermidis S. epidermidis + sTLR2 
sTLR2 
modulatory 
effect 
(%)*** 
Gene 
symbol 
Description 
Fold 
Change ** 
P-value ** 
Fold 
Change**  
P-value **  
Ccl12 Chemokine (C-C motif) ligand 12, MCP5 12.4 0.008 9.4 0.023 -26.0 
Ccl3 Chemokine (C-C motif) ligand 3, MIP1a 4.3 0.033 5.2 0.005 25.8 
Ccr2 Chemokine (C-C motif) receptor 2 4.2 0.043 2.5 0.082 -53.7 
Cxcr4 Chemokine (C-X-C motif) receptor 4 2.1 0.036 1.7 0.113 -31.4 
Fasl Fas ligand (TNF superfamily, member 6) 8.0 0.048 3.2 0.209 -68.1 
Hgf Hepatocyte growth factor 9.8 0.048 3.7 0.050 -69.6 
Ifng Interferon gamma 14.1 0.018 15.2 0.004 8.4 
Il10 Interleukin 10 8.7 0.010 2.5 0.001 -80.2 
Il1b Interleukin 1 beta 7.8 0.046 5.5 0.049 -34.0 
Il6 Interleukin 6 3.1 0.001 1.4 0.218 -79.3 
Itga2 Integrin alpha 2 5.4 0.019 3.6 0.076 -41.9 
Itgb3 Integrin beta 3 2.2 0.001 1.6 0.001 -47.9 
Mmp13 Matrix metallopeptidase 13 4.4 0.037 1.5 0.344 -84.0 
Myc Myelocytomatosis oncogene 2.1 0.005 1.7 0.078 -41.7 
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 3.5 0.022 2.1 0.002 -55.2 
Smad2 MAD homolog 2 (Drosophila) 2.0 0.018 1.4 0.037 -58.8 
Sp1 Trans-acting transcription factor 1 2.2 0.002 1.5 0.046 -58.8 
Stat1 Signal transducer and activator of transcription 1 8.1 0.046 6.4 0.041 -24.0 
Tgfbr1 Transforming growth factor, beta receptor I 2.3 0.001 1.6 0.101 -53.1 
Timp1 Tissue inhibitor of metalloproteinase 1 3.2 0.028 1.5 0.233 -76.3 
Tnf Tumor necrosis factor 8.1 0.042 14.3 0.043 88.5 
*Only statistically significant (P<0.05) S. epidermidis-induced ≤ 0.5 or ≥ 2 fold changes were considered.  
**Compared to Control group. 
***Compared to the effect of S. epidermidis treatment. Genes affected ≥20% are shown in blue (inhibition) or green (upregulation). 
 
Table 4. Changes in fibrosis-related peritoneal gene expression at day 49 in mice infected with S. epidermidis or S. 
epidermidis + sTLR2. 
  S. epidermidis S. epidermidis + sTLR2 sTLR2 
modulatory 
effect (%)** 
Gene 
symbol 
Description 
Fold 
Change * 
P-value * 
Fold 
Change*  
P-value * 
Fasl Fas ligand (TNF superfamily, member 6) 2.6 0.236 0.9 0.907 -105.2 
Mmp1a Matrix metallopeptidase 1a (interstitial collagenase) 0.5 0.001 0.7 0.207 -48.1 
Mmp3 Matrix metallopeptidase 3 0.4 0.011 0.9 0.506 -87.7 
Mmp9 Matrix metallopeptidase 9 0.4 0.024 0.5 0.019 -16.6 
Timp1 Tissue inhibitor of metalloproteinase 1 0.6 0.220 0.3 0.036 N/A 
*Compared to Control group. 
**Compared to the effect of S. epidermidis treatment. 
N/A, not applicable. 
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Figure 1. Peritoneal leukocytes and mesothelial cells differentially express TLR2, TLR4 and C5aR and respond to
TLR agonists or C5a. (A) Expression levels of TLR2, TLR4, C5aR, the TLR co-receptor CD14 and the C5aR
negative regulator C5L2 in PDE-isolated resident peritoneal macrophages, lymphocytes and peritoneal mesothelial
cells (from omentum), as determined by flow cytometry. Results are from the analysis of cells isolated from PDE or
omentum of 7 to 10 different donors. *, P<0.05; ***, P<0.005. (B) IL-8 levels in culture supernatants of resident
peritoneal leukocytes, macrophages, lymphocytes and peritoneal mesothelial cells stimulated overnight with the
indicated concentrations of various TLR agonists or C5a. Leukocytes, macrophages and lymphocytes were from the
same patient sample. Results shown are the mean (± SD) from one experiment representative of three performed
with cells from different donors.
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Figure 2. Synergism between TLRs and C5aR in peritoneal macrophages,
but not in peritoneal mesothelial cells, enhances pro- and anti-inflammatory
and fibrotic mediator release. Levels of pro-inflammatory cytokines and fibrotic
markers in the culture supernatants of PDE-isolated resident peritoneal
leukocytes (A, C, D) or peritoneal mesothelial cells (from omentum, B)
stimulated overnight with the indicated concentrations of Pam3Cys (or 250
ng/ml), LPS (or 1 ng/ml) or heat-killed E. coli in the presence or absence of
increasing concentrations of C5a. In (C) cells were pre-incubated with an anti-
C5L2 blocking mAb (1D9, 5 μg/ml). IL-8, IL-13, TGF-β and TIMP-1 levels
were determined by ELISA, and IL-6, IL-10, TNF-α, MMP-1, MMP-3 and
MMP-9 by multiplex ELISA (Meso Scale Discovery). Results are from one
experiment (± SD) representative of 10 (A and B) or 5 (C and D), performed
with cells from different donors. The P values (*) indicate statistical
significance for the comparison between the additive response to a TLR
agonist alone and C5a alone vs the response to the combination of TLR
agonist + C5a. *, P<0.05; **, P<0.01; ***, P<0.005.
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Figure 3. TLR2, TLR4, C5aR and C5L2 differentially contribute to bacteria-induced peritoneal fibrosis development in
mouse peritonitis models. (A-D) Wild-type (WT), TLR2 deficient (TLR2-/-), TLR4-/-, C5aR-/- or C5L2-/- mice (n=5 per
group) were inoculated intraperitoneally 4 times at weekly intervals with heat-killed S. epidermidis (S. epi., 5 x 108
CFU/mouse) or Escherichia coli (E. coli, 2 x 107 CFU/mouse), or left untreated (control). Four weeks after the last
injection, histological analysis of the peritoneal membrane was conducted. Sections of peritoneal membrane (5 µm)
were stained with haematoxylin/eosin and the thickness of the sub-mesothelial compact zone (SMC, layer between
the muscle and membrane surface) was determined using the Leica Qwin imaging software. Representative fields
(x40 magnification) are shown. Bar plots show the mean (± SEM) of SMC thickness in each experimental group. The
mean of SMC was determined as described in Concise Methods. *, P<0.05; ***, P<0.005.
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Figure 4. TLR2, TLR4 and C5aR are involved in bacteria-induced pro-fibrotic and inflammatory responses of
peritoneal leukocytes from uremic PD patients. Levels of pro-fibrotic and inflammatory cytokines released by PDE-
isolated uremic leukocytes cultured overnight with or without heat-killed S. epidermidis (107 cfu/ml) or E. coli. (106
cfu/ml) in the presence of the indicated blocking mAbs or isotype-matched control (5 μg/ml). To maintain the uremic
milieu throughout the experiments, the culture medium was supplemented with the patients’ own PDE (1/2 dilution).
The uremic status of the patients was confirmed by urea and creatinine measurements in the blood and PDE (inset
table). Results are the mean (± SD) of triplicates after background subtraction (cells cultured in the absence of
bacteria, but presence of the blocking mAbs or isotype control, typically IL-8 < 1ng/ml, IL-6 < 100 pg/ml, IL-13 < 25
pg/ml, TGFβ < 10 pg/ml). *, P<0.05; **, P <0.01; ***, P <0.005 (specific mAb vs isotype control, Student’s t test).
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Figure 5. Differential involvement of TLR2, TLR4, CD14 and C5aR in PD-induced sterile peritoneal inflammation. (A)
Levels of pro-fibrotic (A) and inflammatory (B) cytokines released by PDE-isolated uremic leukocytes stimulated
(17h) with non-infected PDE (PDE #1: urea:16.6 mM, creatinine: 286.4 µM; PDE #2: urea: 15.8 mM, creatinine:
415.5 µM) in the presence of the indicated blocking mAbs or isotype-matched control (5 μg/ml). The non-infected
PDEs used for stimulation also served to maintain uremic conditions throughout the experiment. The uremic status of
the patients was confirmed by urea and creatinine measurements in the blood and PDE (A, inset table). Results are
the mean (± SD) of triplicates after background subtraction (cells cultured in the absence of PDE, but presence of the
mAbs, typically IL-8 < 1ng/ml, IL-6 < 100 pg/ml, IL-13 < 25 pg/ml, TGFβ < 10 pg/ml). *, P<0.05; **, P <0.01; ***, P
<0.005 (specific mAb vs isotype control, Student’s t test). Results in B are from patient D. (C) Western blot analysis
and densitometric scanning of HMGB-1 detected in sterile PDE samples (diluted 20 times) from seven donors.
Arrows point at the HMGB-1 protein specifically detected. The dashed line in the inset indicates separate gels.
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Figure 6. The intensity of the TLR-mediated inflammatory episodes, in addition to their number, impacts on peritoneal
fibrosis development. C57BL/6J mice (n=5 per group) were inoculated intraperitoneally 4 times (A) or 2 times (B) at
weekly intervals with live (A) or heat-killed (B) S. epidermidis (5 x 108 CFU/mouse) or PBS (control), in the presence
or absence of a TLR2-derived peptide (p9 or control p17; 20 μg/mouse). Four weeks after the last injection,
histological analysis of the peritoneal membrane was conducted as described for Figure 3. Representative fields (x40
magnification) are shown, and bar plots show the mean (± SEM) of the sub-mesothelial compact zone (SMC)
thickness for each group. ***, P<0.005. (A, inset) At the indicated time points following the first injection, peritoneal
lavages were obtained. PMN and monocyte numbers were determined by flow cytometry using anti-Ly6G and anti-7/4
specific monoclonal antibodies, and bacterial titers by overnight culture on microbiological agar plates.*, P<0.05; **,
P<0.01; ***, P<0.005 (S. epi. + p9 vs S. epi. alone).
AC
B
PDE 
N
o
n
-
in
fe
c
te
d
In
fe
c
te
d
 
sTLR2 
75 kDa
*
Non-infected 
PDE
Infected 
PDE
1038
644
s
T
L
R
2
 (
p
g
/m
l)
0
200
400
600
800
1000
1200
1400
1600
1800
No stimulation
S. epi.
E. coli
sTLR2 
75 kDa
Non-infected PDE
#3 #4 #5#1 #2
IL
-8
 (
p
g
/m
l)
Sterile  PDE (dilution)
***
0
200
400
600
800
1000
1200
1400
1/10 1/2
No depletion
Mock depletion
sTLR2 depletion
E
s
T
L
R
2
 (
p
g
/m
l)
Days post-infection
#1
#2
#3
#4
Peritonitis patient
PD effluent 
#5
0
500
1000
1500
2000
2500
3000
3500
0 1 2 3 4 5 6 7 8
D
0
5000
10000
15000
20000
#1 #2 #3 #4 #5
s
T
L
R
2
 
(D
e
n
s
it
o
m
e
tr
y
 u
n
it
s
)
sTLR2 
75 kDa
s
T
L
R
2
 (
p
g
/m
l)
0
50
100
150
200
250
300
350
400
F
IL
-8
 (
p
g
/m
l)
Infected  PDE
(1/2 dilution)
Sterile  PDE 
(1/2 dilution)
0
100
200
300
400
500
600
0
5000
10000
15000
20000
25000
30000
35000
No sTLR2
+ sTLR2
*
***
Figure 7. sTLR2 is present in PD effluent from non-infected patients and can reduce PD-induced pro-inflammatory
responses ex vivo. (A) Western blot analysis and densitometric scanning of sTLR2 detected in sterile PDE from
different donors. (B) Levels of sTLR2 in the culture supernatants of peritoneal mesothelial cells, sterile PDE-isolated
lymphocytes and macrophages stimulated (16h) or not with heat-killed S. epidermidis (5 x 108 CFU/ml) or E. coli (5
x 107 CFU/ml). Results are from one experiment representative of three, performed with cells from different donors.
(C and D) Levels of sTLR2 in PDE from patients without or with ongoing peritoneal infection tested at day 1 (C) or
at the indicated times post-infection (D). Inset in (C) shows a representative sTLR2 Western blot profile in the PDE
of one patient before and on day 1 of infection. In (D), results are expressed as means (± SD) for each time point. *,
P <0.05. (E and F) Levels of IL-8 in the culture supernatant of PBMC (E) or PDE leukocytes (F) cultured overnight
with the indicated dilutions of sterile or infected cell-free PDE depleted of sTLR2, mock-depleted or not depleted
(E), or supplemented with 500 ng/ml of human recombinant sTLR2 (F). Depletion in (E) was ~80%, as estimated by
Western Blot. Results are from one experiment (± SD) representative of three performed with cell-free PDE from
different donors. *, P<0.05; ***, P<0.005 (sTLR2 depleted vs mock depleted or + sTLR2 vs no sTLR2).
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Figure 8. sTLR2 inhibits infection-induced peritoneal fibrosis development in vivo. (A-F) C57BL/6J mice (n=5 per
group) were inoculated intraperitoneally 4 times at weekly intervals (A, C, F) or once (B, D, E) with live S.
epidermidis (5 x 108 CFU/mouse, A-E) or heat-killed Escherichia coli (5 x 107 CFU/mouse, F) in the presence or
absence of sTLR2 (250 ng/mouse). In (A and F), four weeks after the last injection (day 49), histological analysis of
the peritoneal membrane was conducted as described for Figure 3. Representative fields (x40 magnification) are
shown; bar plots show the mean (± SEM) of the sub-mesothelial compact zone (SMC) thickness for each group. In
(B, D and E), the animals were sacrificed at the indicated time points after the injection and peritoneal lavages and
blood were obtained. Cytokine levels were determined by ELISA, PMN and monocyte numbers by flow cytometry
using anti-Ly6G and anti-7/4 specific monoclonal antibodies, and bacterial titers by overnight culture on
microbiological agar plate. *, P<0.05; **, P<0.01; ***, p<0.005 (S. epi + sTLR2 vs S. epi. alone). In (C), scatter plots
show the effect of sTLR2 on the S. epidermidis-induced modulation of fibrosis-related genes, as assessed by RT-
qPCR on RNA extracted from peritoneal membranes one week after the fourth injection (day 28).
 SUPPLEMENTAL MATERIAL 
 
Figure 1. Co-stimulation via TLR4 and C5aR in peripheral blood mononuclear 
cells results in a synergistically enhanced pro-inflammatory response. Levels of 
IL-8 (ELISA) in the culture supernatant of PBMC (1.5 x 105 cells/ well in 
triplicates) cultured (14h) in the presence or absence of LPS (10 ng/ml) and C5a 
(2.5 nM). Synergism was assessed by comparing the additive response to each 
individual ligand (No LPS + C5a or + LPS No C5a) with that of the combination 
of ligands (+ LPS + C5a). Results are from one experiment (±SD) representative 
of three. ***, P< 0.005, C5a treatment + LPS treatment vs C5a + LPS treatment. 
 
 
 
Figure 2. Repeated peritoneal inoculation of Gram-
positive bacteria and bacterial components induces 
peritoneal fibrosis development in mice. Mice (n=5 per 
group) were intraperitoneally inoculated 4 times at 
weekly intervals with live or heat-killed S. epidermidis 
(5 x 108 CFU/mouse), a cell-free supernatant from S. 
epidermidis cultures (SES), PBS or left untreated (No 
i.p.). Four weeks after the last injection, histological 
analysis of the peritoneal membrane was conducted. 
Sections of peritoneal membrane (5 µm) were stained 
with haematoxylin/eosin and the thickness of the sub-
mesothelial compact zone (SMC, layer between the 
muscle and membrane surface) was determined using 
the Leica Qwin imaging software. The mean of SMC 
was determined as described in Concise Methods. 
Three different fields of view were examined for each 
animal, 6 measurements were made per field and the average of the 10 highest measurements was taken as 
mean of SMC thickness. **, P<0.01; ***, P<0.005. 
 
Figure 3. Testing for bacterial DNA in non-infected PD  
effluents. Total DNA was extracted from non-infected cell-
free PDE by a chelex-based method as previously 
described54. One PDE sample was spiked with heat-killed S. 
epidermidis prior to extraction to serve as a positive control. 
Pan-bacterial DNA was then amplified by qPCR using the 
FemtoTM Bacterial DNA Quantification kit (Zymo research), 
and the amount of DNA in PDE was determined using the 
kit’s internal standard curve as a reference. A Ct of 30 
cycles, corresponding to 10 fg of bacterial DNA per 1ml of 
PDE, was set as PDE sterility cut off. Representative 
examples of the Ct values obtained for non-infected PDE 
(blue diamonds) and positive controls (red square) are 
shown together with a typical standard curve. 
 
 
 
 
 
 Figure 4. Flow cytometric 
analysis of leukocytes in non-
infected PD effluents. 
Peritoneal leukocytes were 
prepared from non-infected 
PDE and analysed by flow 
cytometry as described in 
Concise Methods. The dot plot 
and fluorescence histogram 
show a representative forward 
and side scatter and the typical 
CD14 expression profile, 
respectively, of the total live 
peritoneal leukocyte population 
following dead cells  exclusion (eFluor viability dye, <15%). Lymphocytes and macrophages (representative 
percentages shown) were identified based on their forward and side scatter profiles and CD14 expression levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Effect of blocking TLR2 in uremic peritoneal leukocytes on S. epidermidis-induced fibrosis-related gene expression 
(complete array).* 
 S. epidermidis S. epidermidis + anti-TLR2 
Gene 
symbol 
Description 
Fold 
Change** P-value** 
Fold 
Change**  P-value** 
Acta2 Actin, alpha 2, smooth muscle, aorta 1.0 0.789 1.0 0.946 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.0 0.757 1.0 0.903 
Akt1 V-akt murine thymoma viral oncogene homolog 1 1.1 0.691 0.9 0.796 
Bcl2 B-cell CLL/lymphoma 2 0.8 0.232 0.8 0.383 
Bmp7 Bone morphogenetic protein 7 1.6 0.291 0.6 0.199 
Cav1 Caveolin 1, caveolae protein, 22kDa 0.5 0.034 0.5 0.039 
Ccl11 Chemokine (C-C motif) ligand 11 0.5 0.018 0.7 0.137 
Ccl2 Chemokine (C-C motif) ligand 2 12.0 0.001 14.5 0.001 
Ccl3 Chemokine (C-C motif) ligand 3 16.5 0.001 3.2 0.065 
Ccr2 Chemokine (C-C motif) receptor 2 0.3 0.010 0.4 0.015 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.6 0.215 1.5 0.351 
Col1a2 Collagen, type I, alpha 2 0.7 0.101 0.7 0.063 
Col3a1 Collagen, type III, alpha 1 0.7 0.021 0.7 0.015 
Ctgf Connective tissue growth factor 0.4 0.048 0.4 0.040 
Cxcr4 Chemokine (C-X-C motif) receptor 4 1.8 0.102 1.8 0.056 
Dcn Decorin 1.1 0.402 1.0 0.928 
Edn1 Endothelin 1 14.9 0.001 11.0 0.006 
Egf Epidermal growth factor 1.0 0.757 1.0 0.903 
Eng Endoglin 0.5 0.011 0.5 0.016 
Faslg Fas ligand (TNF superfamily, member 6) 1.6 0.001 1.9 0.001 
Grem1 Gremlin 1 0.2 0.001 0.4 0.001 
Hgf Hepatocyte growth factor (hepapoietin A; scatter factor) 0.6 0.026 0.5 0.020 
Ifng Interferon, gamma 55.2 0.001 63.5 0.001 
Il10 Interleukin 10 240.8 0.001 188.9 0.001 
Il13 Interleukin 13 10.1 0.026 9.5 0.047 
Il13ra2 Interleukin 13 receptor, alpha 2 1.9 0.002 1.7 0.002 
Il1a Interleukin 1, alpha 19.7 0.001 18.9 0.001 
Il1b Interleukin 1, beta 31.8 0.011 30.1 0.004 
Il4 Interleukin 4 1.0 0.757 1.0 0.903 
Il5 Interleukin 5  1.3 0.221 0.4 0.035 
Ilk Integrin-linked kinase 1.5 0.049 1.3 0.199 
Inhbe inhibin, beta E 1.0 0.757 1.0 0.903 
Itga1 Integrin, alpha 1 9.5 0.001 9.4 0.001 
Itga2 Integrin, alpha 2  1.4 0.118 1.2 0.362 
Itga3 Integrin, alpha 3  0.7 0.066 0.6 0.076 
Itgav Integrin, alpha V  2.6 0.004 3.3 0.002 
Itgb1 Integrin, beta 1  1.3 0.266 1.4 0.180 
Itgb3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 5.7 0.001 6.6 0.002 
Itgb5 Integrin, beta 5 0.3 0.001 0.3 0.004 
Itgb6 Integrin, beta 6 1.9 0.013 1.2 0.339 
Itgb8 Integrin, beta 8 12.6 0.004 13.7 0.011 
Jun Jun proto-oncogene 0.9 0.628 0.9 0.930 
Lox Lysyl oxidase 1.0 0.841 0.9 0.478 
Ltbp1 Latent transforming growth factor beta binding protein 1 0.6 0.134 0.6 0.209 
Mmp1 Matrix metallopeptidase 1 (interstitial collagenase) 67.1 0.001 61.1 0.001 
Mmp13 Matrix metallopeptidase 13 (collagenase 3) 1.0 0.757 1.0 0.903 
Mmp14 Matrix metallopeptidase 14 (membrane-inserted) 3.6 0.013 2.6 0.203 
Mmp2 Matrix metallopeptidase 2 (gelatinase A) 2.0 0.008 1.7 0.022 
Mmp3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 5.5 0.001 3.6 0.001 
Mmp8 Matrix metallopeptidase 8 (neutrophil collagenase) 3.5 0.001 4.7 0.002 
Mmp9 Matrix metallopeptidase 9 (gelatinase B) 0.7 0.035 0.8 0.260 
Myc V-myc myelocytomatosis viral oncogene homolog (avian) 0.9 0.728 0.8 0.012 
Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 1.5 0.228 1.7 0.140 
Pdgfa Platelet-derived growth factor alpha polypeptide 1.8 0.013 2.2 0.009 
Pdgfb Platelet-derived growth factor beta polypeptide 0.9 0.674 1.2 0.599 
Plat Plasminogen activator, tissue 0.2 0.092 0.2 0.086 
Plau Plasminogen activator, urokinase 1.1 0.828 1.1 0.712 
Plg Plasminogen 2.8 0.031 1.0 0.903 
Serpina1 Serpin peptidase inhibitor, clade A, member 1 9.7 0.001 8.8 0.001 
*Statistically significant (P<0.05) and biologically relevant (≤ 0.5, bold gold or ≥ 2, bold red) S. epidermidis-induced fold changes are analysed in Results, Table 1  
**Compared to Control group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serpine1 Serpin peptidase inhibitor, clade E, member 1 1.7 0.035 1.5 0.095 
Serpinh1 Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 1.2 0.002 1.2 0.094 
Smad2 SMAD family member 2 1.3 0.099 1.3 0.111 
Smad3 SMAD family member 3 0.6 0.281 0.5 0.193 
Smad4 SMAD family member 4 1.4 0.320 1.4 0.304 
Smad6 SMAD family member 6 0.6 0.007 0.3 0.001 
Smad7 SMAD family member 7 1.0 0.979 1.0 0.961 
Snai1 Snail homolog 1 (Drosophila) 7.2 0.049 5.3 0.063 
Sp1 Sp1 transcription factor 1.0 0.894 1.4 0.135 
Stat1 Signal transducer and activator of transcription 1, 91kDa 2.5 0.010 2.6 0.012 
Stat6 Signal transducer and activator of transcription 6, interleukin-4 induced 1.0 0.915 1.1 0.619 
Tgfb1 Transforming growth factor, beta 1 0.7 0.032 0.6 0.052 
Tgfb2 Transforming growth factor, beta 2 1.4 0.077 1.4 0.066 
Tgfb3 Transforming growth factor, beta 3 2.0 0.015 2.1 0.060 
Tgfbr1 Transforming growth factor, beta receptor 1 0.9 0.589 0.8 0.515 
Tgfbr2 Transforming growth factor, beta receptor II (70/80kDa) 0.4 0.064 0.4 0.066 
Tgif1 TGFB-induced factor homeobox 1 2.3 0.032 2.3 0.041 
Thbs1 Thrombospondin 1 0.7 0.126 0.5 0.035 
Thbs2 Thrombospondin 2 0.8 0.143 0.5 0.018 
Timp1 TIMP metallopeptidase inhibitor 1 1.9 0.093 1.6 0.193 
Timp2 TIMP metallopeptidase inhibitor 2 0.6 0.093 0.6 0.118 
Timp3 TIMP metallopeptidase inhibitor 3 0.3 0.001 0.3 0.001 
Timp4 TIMP metallopeptidase inhibitor 4 0.4 0.021 0.4 0.022 
Tnf Tumor necrosis factor 4.9 0.002 4.7 0.001 
Vegfa Vascular endothelial growth factor A 6.8 0.001 6.8 0.000 
Table 2. Effect of blocking TLR2 in uremic peritoneal leukocytes on non-infected PDE-induced fibrosis-related gene 
expression (complete array).* 
 Non-infected PDE 
Non-infected PDE + anti-
TLR2 
Gene 
symbol 
Description 
Fold 
Change** 
P-value** 
Fold 
Change**  
P-value** 
Acta2 Actin, alpha 2, smooth muscle, aorta 1.0 0.886 1.0 0.836 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 0.8 0.291 1.1 0.835 
Akt1 V-akt murine thymoma viral oncogene homolog 1 0.7 0.007 0.7 0.025 
Bcl2 B-cell CLL/lymphoma 2 0.7 0.001 0.5 0.001 
Bmp7 Bone morphogenetic protein 7 1.8 0.175 1.2 0.844 
Cav1 Caveolin 1, caveolae protein, 22kDa 1.0 0.843 1.5 0.011 
Ccl11 Chemokine (C-C motif) ligand 11 1.3 0.490 1.1 0.835 
Ccl2 Chemokine (C-C motif) ligand 2 2.2 0.017 1.1 0.883 
Ccl3 Chemokine (C-C motif) ligand 3 0.6 0.001 0.3 0.001 
Ccr2 Chemokine (C-C motif) receptor 2 1.3 0.014 0.9 0.193 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 0.8 0.028 0.4 0.001 
Col1a2 Collagen, type I, alpha 2 1.4 0.217 1.2 0.514 
Col3a1 Collagen, type III, alpha 1 2.1 0.245 1.7 0.472 
Ctgf Connective tissue growth factor 1.0 0.640 0.9 0.006 
Cxcr4 Chemokine (C-X-C motif) receptor 4 1.3 0.027 0.9 0.364 
Dcn Decorin 1.0 0.540 1.3 0.001 
Edn1 Endothelin 1 1.7 0.120 0.5 0.163 
Egf Epidermal growth factor 6.5 0.001 1.1 0.835 
Eng Endoglin 0.9 0.552 0.7 0.034 
Faslg Fas ligand (TNF superfamily, member 6) 0.9 0.196 1.1 0.692 
Grem1 Gremlin 1 0.8 0.068 1.2 0.405 
Hgf Hepatocyte growth factor (hepapoietin A; scatter factor) 1.0 0.852 2.2 0.018 
Ifng Interferon, gamma 0.7 0.208 1.4 0.265 
Il10 Interleukin 10 0.9 0.220 1.0 0.879 
Il13 Interleukin 13 3.5 0.001 3.9 0.011 
Il13ra2 Interleukin 13 receptor, alpha 2 7.3 0.002 6.7 0.004 
Il1a Interleukin 1, alpha 0.6 0.036 0.1 0.001 
Il1b Interleukin 1, beta 0.6 0.004 0.1 0.001 
Il4 Interleukin 4 4.2 0.001 3.8 0.014 
Il5 Interleukin 5  1.5 0.054 1.9 0.002 
Ilk Integrin-linked kinase 0.8 0.051 0.6 0.007 
Inhbe inhibin, beta E 1.0 0.708 0.4 0.435 
Itga1 Integrin, alpha 1 1.3 0.001 0.9 0.501 
Itga2 Integrin, alpha 2  1.6 0.001 1.8 0.077 
Itga3 Integrin, alpha 3  0.7 0.031 0.8 0.479 
Itgav Integrin, alpha V  0.9 0.007 0.9 0.166 
Itgb1 Integrin, beta 1  1.1 0.708 0.9 0.632 
Itgb3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 0.8 0.009 0.6 0.001 
Itgb5 Integrin, beta 5 1.0 0.973 1.2 0.328 
Itgb6 Integrin, beta 6 0.8 0.291 1.1 0.835 
Itgb8 Integrin, beta 8 1.6 0.032 0.5 0.030 
Jun Jun proto-oncogene 0.8 0.537 0.5 0.035 
Lox Lysyl oxidase 1.1 0.311 1.3 0.043 
Ltbp1 Latent transforming growth factor beta binding protein 1 0.7 0.126 1.3 0.136 
Mmp1 Matrix metallopeptidase 1 (interstitial collagenase) 1.4 0.001 0.9 0.404 
Mmp13 Matrix metallopeptidase 13 (collagenase 3) 4.1 0.001 1.1 0.835 
Mmp14 Matrix metallopeptidase 14 (membrane-inserted) 0.5 0.001 0.2 0.001 
Mmp2 Matrix metallopeptidase 2 (gelatinase A) 0.9 0.214 1.1 0.289 
Mmp3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 0.9 0.344 0.6 0.014 
Mmp8 Matrix metallopeptidase 8 (neutrophil collagenase) 1.1 0.794 1.1 0.759 
Mmp9 Matrix metallopeptidase 9 (gelatinase B) 0.8 0.005 1.3 0.004 
Myc V-myc myelocytomatosis viral oncogene homolog (avian) 1.1 0.001 1.0 0.476 
Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 0.6 0.001 0.3 0.001 
Pdgfa Platelet-derived growth factor alpha polypeptide 0.8 0.204 1.2 0.373 
Pdgfb Platelet-derived growth factor beta polypeptide 0.6 0.001 0.8 0.004 
Plat Plasminogen activator, tissue 0.5 0.001 0.5 0.001 
Plau Plasminogen activator, urokinase 1.0 0.724 0.4 0.001 
Plg Plasminogen 0.8 0.291 1.1 0.835 
*Statistically significant (P<0.05) and biologically relevant (≤ 0.5, bold gold or ≥ 2, bold red) PDE #1-induced fold changes are analysed in Results, Table 2  
**Compared to Control group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serpina1 Serpin peptidase inhibitor, clade A, member 1 1.0 0.505 0.6 0.001 
Serpine1 Serpin peptidase inhibitor, clade E, member 1 0.9 0.531 0.7 0.089 
Serpinh1 Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 1.0 0.357 1.3 0.004 
Smad2 SMAD family member 2 0.9 0.399 0.8 0.214 
Smad3 SMAD family member 3 0.4 0.019 0.2 0.005 
Smad4 SMAD family member 4 1.1 0.647 0.9 0.435 
Smad6 SMAD family member 6 0.6 0.022 0.6 0.005 
Smad7 SMAD family member 7 1.0 0.972 0.6 0.432 
Snai1 Snail homolog 1 (Drosophila) 1.3 0.307 0.7 0.336 
Sp1 Sp1 transcription factor 1.1 0.319 0.9 0.707 
Stat1 Signal transducer and activator of transcription 1, 91kDa 1.3 0.005 2.9 0.001 
Stat6 Signal transducer and activator of transcription 6, interleukin-4 induced 1.2 0.270 1.0 0.899 
Tgfb1 Transforming growth factor, beta 1 0.8 0.036 0.6 0.034 
Tgfb2 Transforming growth factor, beta 2 1.0 0.914 0.6 0.002 
Tgfb3 Transforming growth factor, beta 3 0.9 0.314 0.8 0.091 
Tgfbr1 Transforming growth factor, beta receptor 1 0.9 0.753 0.7 0.008 
Tgfbr2 Transforming growth factor, beta receptor II (70/80kDa) 1.2 0.587 0.9 0.523 
Tgif1 TGFB-induced factor homeobox 1 1.4 0.258 1.3 0.356 
Thbs1 Thrombospondin 1 1.0 0.940 0.2 0.004 
Thbs2 Thrombospondin 2 0.9 0.170 0.7 0.004 
Timp1 TIMP metallopeptidase inhibitor 1 1.0 0.835 0.7 0.037 
Timp2 TIMP metallopeptidase inhibitor 2 1.5 0.040 1.5 0.103 
Timp3 TIMP metallopeptidase inhibitor 3 0.8 0.023 2.3 0.001 
Timp4 TIMP metallopeptidase inhibitor 4 0.5 0.007 1.3 0.042 
Tnf Tumor necrosis factor 0.8 0.030 0.3 0.001 
Vegfa Vascular endothelial growth factor A 1.2 0.088 0.5 0.003 
Table 3. Changes in fibrosis-related peritoneal gene expression (complete fibrosis array) at day 28 in mice infected with S. 
epidermidis or S. epidermidis + sTLR2.* 
 S. epidermidis S. epidermidis + sTLR2 
Gene 
symbol 
Description 
Fold 
Change** P-value** 
Fold 
Change**  P-value** 
Acta2 Actin, alpha 2, smooth muscle, aorta 1.1 0.133 1.1 0.339 
Agt Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.1 0.304 0.8 0.390 
Akt1 Thymoma viral proto-oncogene 1 1.7 0.048 1.3 0.315 
Bcl2 B-cell leukemia/lymphoma 2 1.5 0.167 1.3 0.333 
Bmp7 Bone morphogenetic protein 7 1.9 0.029 1.7 0.068 
Cav1 Caveolin 1, caveolae protein 1.5 0.062 1.2 0.283 
Ccl11 Chemokine (C-C motif) ligand 11 1.0 0.772 1.0 0.992 
Ccl12 Chemokine (C-C motif) ligand 12 12.4 0.008 9.4 0.023 
Ccl3 Chemokine (C-C motif) ligand 3, MIP1a 4.3 0.033 5.2 0.005 
Ccr2 Chemokine (C-C motif) receptor 2 4.2 0.043 2.5 0.082 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.8 0.001 1.4 0.099 
Col1a2 Collagen, type I, alpha 2 1.1 0.625 0.7 0.105 
Col3a1 Collagen, type III, alpha 1 1.1 0.507 0.9 0.760 
Ctgf Connective tissue growth factor 1.6 0.138 3.2 0.034 
Cxcr4 Chemokine (C-X-C motif) receptor 4 2.1 0.036 1.7 0.113 
Dcn Decorin 1.1 0.593 1.1 0.669 
Edn1 Endothelin 1 0.8 0.078 1.0 0.972 
Egf Epidermal growth factor 1.8 0.004 1.3 0.103 
Eng Endoglin 1.7 0.001 1. 0.080 
Fasl Fas ligand (TNF superfamily, member 6) 8.0 0.048 3.2 0.209 
Grem1 Gremlin 1 1.2 0.527 0.8 0.283 
Hgf Hepatocyte growth factor 9.8 0.048 3.7 0.050 
Ifng Interferon gamma 14.1 0.018 15.3 0.004 
Il10 Interleukin 10 8.7 0.010 2.5 0.001 
Il13 Interleukin 13 0.7 0.152 1.0 0.688 
Il13ra2 Interleukin 13 receptor, alpha 2 0.9 0.765 1.0 0.841 
Il1a Interleukin 1 alpha 1.0 0.714 0.4 0.091 
Il1b Interleukin 1 beta 7.8 0.046 5.5 0.049 
Il4 Interleukin 4 0.9 0.677 1.1 0.515 
Il5 Interleukin 5 2.3 0.234 2.7 0.251 
Il6 Interleukin 6 3.1 0.001 1.4 0.218 
Ilk Integrin linked kinase 1.2 0.324 1.1 0.549 
Inhbe Inhibin beta E 1.2 0.530 1.1 0.841 
Itga1 Integrin alpha 1 1.8 0.002 1.5 0.057 
Itga2 Integrin alpha 2 5.4 0.019 3.6 0.076 
Itga3 Integrin alpha 3 1.0 0.909 0.8 0.137 
Itgav Integrin alpha V 1.5 0.100 1.1 0.562 
Itgb1 Integrin beta 1 (fibronectin receptor beta) 1.9 0.019 1.4 0.120 
Itgb3 Integrin beta 3 2.2 0.000 1.6 0.000 
Itgb5 Integrin beta 5 1.6 0.000 1.3 0.024 
Itgb6 Integrin beta 6 1.2 0.138 0.9 0.245 
Itgb8 Integrin beta 8 3.1 0.080 2.7 0.125 
Jun Jun oncogene 1.6 0.016 1.6 0.023 
Lox Lysyl oxidase 1.0 0.817 1.1 0.564 
Ltbp1 Latent transforming growth factor beta binding protein 1 1.9 0.103 1.7 0.077 
Mmp13 Matrix metallopeptidase 13 4.4 0.037 1.5 0.344 
Mmp14 Matrix metallopeptidase 14 (membrane-inserted) 1.8 0.242 1.0 0.998 
Mmp1a Matrix metallopeptidase 1a (interstitial collagenase) 1.2 0.253 1.1 0.283 
Mmp2 Matrix metallopeptidase 2 1.3 0.362 1.3 0.152 
Mmp3 Matrix metallopeptidase 3 0.8 0.263 0.5 0.014 
Mmp8 Matrix metallopeptidase 8 1.7 0.215 1.9 0.070 
Mmp9 Matrix metallopeptidase 9 1.3 0.017 0.4 0.009 
Myc Myelocytomatosis oncogene 2.1 0.005 1.7 0.078 
Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 1.5 0.049 1.1 0.230 
Pdgfa Platelet derived growth factor, alpha 1.1 0.679 1.0 0.748 
Pdgfb Platelet derived growth factor, B polypeptide 1.6 0.060 1.3 0.001 
*Statistically significant (P<0.05) and biologically relevant (≤ 0.5 or ≥ 2) S. epidermidis-induced fold changes in bold red are analysed in Results, Table 3  
**Compared to Control group.  
Plat Plasminogen activator, tissue 0.9 0.482 0.7 0.024 
Plau Plasminogen activator, urokinase 1.4 0.227 1.0 0.698 
Plg Plasminogen 0.9 0.765 1.6 0.411 
Serpina1a Serine (or cysteine) peptidase inhibitor, clade A, member 1a 0.9 0.765 1.1 0.841 
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 3.5 0.022 2.1 0.002 
Serpinh1 Serine (or cysteine) peptidase inhibitor, clade H, member 1 1.3 0.051 1.0 0.874 
Smad2 MAD homolog 2 (Drosophila) 2.0 0.018 1.4 0.037 
Smad3 MAD homolog 3 (Drosophila) 1.6 0.014 1.4 0.192 
Smad4 MAD homolog 4 (Drosophila) 1.4 0.126 1.2 0.355 
Smad6 MAD homolog 6 (Drosophila) 1.4 0.048 1.1 0.598 
Smad7 MAD homolog 7 (Drosophila) 1.7 0.099 1.5 0.178 
Snai1 Snail homolog 1 (Drosophila) 1.7 0.120 1.0 0.864 
Sp1 Trans-acting transcription factor 1 2.2 0.002 1.5 0.046 
Stat1 Signal transducer and activator of transcription 1 8.1 0.046 6.4 0.041 
Stat6 Signal transducer and activator of transcription 6 1.6 0.010 1.2 0.107 
Tgfb1 Transforming growth factor, beta 1 1.9 0.170 1.2 0.042 
Tgfb2 Transforming growth factor, beta 2 1.5 0.050 1.0 0.963 
Tgfb3 Transforming growth factor, beta 3 1.2 0.299 1.2 0.002 
Tgfbr1 Transforming growth factor, beta receptor I 2.4 0.001 1.6 0.101 
Tgfbr2 Transforming growth factor, beta receptor II 1.6 0.021 0.9 0.708 
Tgif1 TGFB-induced factor homeobox 1 1.5 0.575 1.1 0.793 
Thbs1 Thrombospondin 1 2.6 0.139 2.2 0.019 
Thbs2 Thrombospondin 2 1.1 0.477 0.9 0.856 
Timp1 Tissue inhibitor of metalloproteinase 1 3.2 0.028 1.5 0.233 
Timp2 Tissue inhibitor of metalloproteinase 2 1.1 0.528 0.8 0.383 
Timp3 Tissue inhibitor of metalloproteinase 3 1.6 0.006 1.6 0.033 
Timp4 Tissue inhibitor of metalloproteinase 4 0.8 0.834 1.5 0.086 
Tnf Tumor necrosis factor 8.1 0.042 14.3 0.043 
Vegfa Vascular endothelial growth factor A 1.2 0.313 0.9 0.420 
